Introduction {#s1}
============

Motor-mediated intracellular transport is essential for numerous critical cellular processes ([@bib72]; [@bib33]; [@bib91]). This is especially apparent in motor neurons, in which cargoes must be transported over long distances to support various neuronal functions. For instance, the soma is the primary site of metabolic function where RNAs and proteins are synthesized and degraded. Thus, to maintain neuronal health, it is critical that cargoes are transported from the soma to the axon terminus (*i.e.*, along the axon) and vice versa. For example, neurofilaments, which provide structural stability to a cell, are transported to the axon terminus by plus end-directed microtubule motors (kinesins; [@bib100]) and to the soma by the minus end-directed microtubule motor, cytoplasmic dynein (hereafter referred to as dynein) ([@bib22]; [@bib93]; [@bib81]). Dynein has also been shown to play a key role in trafficking numerous other neuronal cargoes in various model organisms ([@bib22]; [@bib93]; [@bib81]; [@bib6]; [@bib4]; [@bib3]; [@bib24]; [@bib73]; [@bib49]; [@bib32]; [@bib40]; [@bib18]; [@bib1]; [@bib67]), including autophagosomes ([@bib68]; [@bib34]; [@bib10]), mitochondria, and ionotropic glutamate receptors ([@bib26]). Defects or perturbations in dynein function lead to mislocalization of these cargoes, and results in an accumulation of protein aggregates at the neurite tip ([@bib68]; [@bib43]). In fact, accumulation of misfolded protein aggregates in the neuronal cytoplasm is a common pathological hallmark for motor neuron disease ([@bib22]; [@bib38]; [@bib47]). Consistent with an important role for dynein in neuronal health ([@bib76]), mouse models with dynein mutations exhibit severe neuropathy, and decreased rates of retrograde axonal transport, among other defects ([@bib20]; [@bib9]; [@bib61]).

In addition to its key role in the retrograde trafficking of cargoes, dynein also plays a critical and conserved role during neuronal development by promoting interkinetic nuclear migration (INM) in neuronal progenitor cells, and in the subsequent migration of young postmitotic neurons. During the former process, which is critical for neurogenesis, nuclear envelope anchored dynein motors promote migration of the nucleus from the basal to the apical surface of the neuroepithelium where mitotic divisions occur ([@bib87]; [@bib28]; [@bib12]). Thus, defects in dynein-mediated nuclear migration can lead to defects in early brain development.

Given its myriad roles in neuronal processes, it is unsurprising that mutations within the catalytic component of the dynein complex (the dynein heavy chain, or DHC, which is encoded by the DYNC1H1 gene) are found in individuals suffering from a wide array of neurodegenerative diseases. For instance, mutations in dynein underlie many cases of malformations of cortical development (MCD), spinal muscular atrophy with lower extremity dominance (SMA-LED), congenital muscular dystrophy (CMD), and Charcot-Marie-Tooth disease (CMT) ([@bib21]; [@bib88]; [@bib80]; [@bib62]; [@bib85]; [@bib94]; [@bib16]). Although mutations in the dynein regulator LIS1 are causative of the MCD disease lissencephaly ([@bib98]; [@bib99]; [@bib71]) (characterized by a smooth brain due to reduced or absent cortical folding), mutations in dynein more often lead to polymicrogyria, which is characterized by excessive small folds in the cerebral cortex ([@bib64]; [@bib39]; [@bib96]; [@bib92]). Although a clear link has been established between dynein dysfunction and various neurological diseases, the underlying molecular basis for disease onset or progression is unknown.

An unambiguous mechanistic dissection of mutant dynein function in animal cells is complicated by the diverse cellular functions in which dynein participates (*e.g.*, axonal transport, centrosome separation, spindle assembly, nuclear envelope breakdown, spindle checkpoint inactivation) ([@bib74]; [@bib19]; [@bib75]; [@bib27]; [@bib97]; [@bib11]), and the difficulties and expense associated with generating and analyzing mutant cell lines (*e.g.*, compromised viability, pleiotropism, heterozygosity). To overcome these issues, we have employed the versatility and power of the budding yeast *Saccharomyces cerevisiae* to understand how mutations found in individuals suffering from various neurological diseases lead to dynein dysfunction. In addition to their genetic amenability, low maintenance costs, and rapid generation time, the study of dynein function in budding yeast is simplified by several factors. In contrast to animal cells in which dynein performs numerous functions, the only known function for dynein in budding yeast is to position the mitotic spindle at the future site of cytokinesis ([@bib44]; [@bib15]; [@bib7]), making functional studies of dynein mutants in this organism simple and unambiguous. As in higher eukaryotes, the yeast dynein complex is comprised of light (Dyn2), light-intermediate (Dyn3), intermediate (Pac11), and heavy chains (Dyn1), the latter of which is the ATPase that powers motility along microtubules (see [Figure 1A](#fig1){ref-type="fig"}) ([@bib54]). Whereas in humans, the non-catalytic subunits exist in different isoforms encoded by multiple genes and tissue-specific isoforms ([@bib63]; [@bib65]), each of the accessory chains in budding yeast is encoded by only a single gene, enabling simple genetic analysis and manipulation. Moreover, studies have revealed a high degree of structural similarity between yeast and human dynein ([@bib8]; [@bib79]), rendering structure-function studies in this organism relevant and translatable to animal cells. Compounded by the genetic amenability, ease of imaging, and the simple one-step method for isolation of recombinant, motile dynein motors ([@bib69]; [@bib52]; [@bib55]), budding yeast are a powerful model system for studies of dynein function.

![Spindle positioning assay provides coarse assessment of mutant dynein dysfunction.\
(**A**) Color-coded cartoon representation of the full-length dynein complex (left; with associated accessory chains; Dyn2, dynein light chain; Dyn3, dynein light-intermediate chain; Pac11, dynein intermediate chain; Dyn1, dynein heavy chain), and a linear schematic of Dyn1 with indicated disease-correlated mutations (right; DD, dimerization domain; CC, coiled-coil; MTBD, microtubule-binding domain). The equivalent human residues and disease-correlated substitutions are indicated in parentheses for each residue. ‡Note that we mistakenly substituted an asparagine for residue R3201 instead of a glutamine, the latter of which was identified as correlating with MCD ([@bib64]). R3201N was used throughout this study. (**B**) Representative fluorescence image (left; green, GFP-Tub1; red, contrast enhanced brightfield image to illustrate cell cortex) and quantitation of spindle positioning phenotypes in the 17 disease-correlated Dyn1 mutants, along with wild-type and dynein knock-out (*dyn1*∆) cells. Each data point represents the fraction of mispositioned anaphase spindles along with standard error (weighted mean ± weighted standard error of proportion; n ≥ 99 anaphase spindles from three independent experiments for each strain). Statistical significance was determined by calculating Z scores, as described in the Materials and methods (\*, p≤0.1; \*\*, p≤0.05; \*\*\*, p≤0.001). Also see [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.004Figure 1---source data 1.Spreadsheet with spindle positioning assay values.](elife-47246-fig1){#fig1}

For this study, we focused on a library of 17 single point mutations in the dynein heavy chain (Dyn1), which are found in patients suffering from a broad spectrum of neurological diseases ([Figure 1A](#fig1){ref-type="fig"}). These mutations were selected based on their conservation with corresponding residues in yeast dynein. Our findings reveal phenotypic signatures associated with the mutant library that range from partial to complete loss-of-function, and even gain-of-function in some respects. In some cases, the altered function was intrinsic to dynein, while in others, the effects could be attributed to alterations in the activity of the holo-dynein-dynactin complex. The rapid nature of our phenotypic analysis combined with the wealth of structural information available for dynein has enabled us to assess the likely structural basis for dysfunction in two instances. Moreover, consistent with recent findings from another group ([@bib25]), our work reveals a correlation between the degree of dynein dysfunction and disease type. Overall, we describe a rapid and unambiguous set of tools that can be used to understand how disease-correlated mutations in dynein genes lead to onset or progression of disease.

Results {#s2}
=======

Budding yeast as a model organism for dynein dysfunction {#s2-1}
--------------------------------------------------------

Genomic alterations in individuals suffering from a variety of neurological diseases have been mapped to numerous unique sites throughout the dynein heavy chain ([Figure 1A](#fig1){ref-type="fig"}). The tail domain (\~1400 amino acids) is the site of interaction for accessory chains (light-intermediate and intermediate chains), as well as adaptors that link dynein to the dynactin regulatory complex and various cellular cargoes ([@bib89]). The motor domain (\~3000 amino acids) forms the catalytic core of dynein, where ATP binding and hydrolysis is translated into movement of the linker element that powers motility along microtubules ([@bib8]; [@bib78]; [@bib72]). Although the genetic basis for dyneinopathies is known, there exists very limited data on how these mutations are causative of motor dysfunction. Indeed, the mutations map throughout the entire heavy chain, with no clear correlation between disease state (*i.e.*, symptoms, severity, age of onset) and mutation identity. To understand how disease-correlated point mutations affect dynein function, we employed a series of well-established methodologies to assess the function of 17 single point mutants in budding yeast.

The first such assessment was to determine if the mutant motors were capable of correctly positioning the mitotic spindle, the only known function for dynein in budding yeast. To this end, we performed a spindle positioning assay using haploid yeast cells expressing mRuby2-Tub1 (α-tubulin; to visualize the mitotic spindle) and the mutant dynein from the native dynein locus. Given the dispensable nature of dynein function for yeast cell viability ([@bib44]; [@bib15]), a complete loss-of-function mutant would not be expected to compromise viability, but to simply affect spindle position. In this assay, single time-point images of mutant cells are acquired, and the position of the mitotic spindle is deemed to be either correct (*i.e.*, the anaphase spindle extended through the bud neck along the mother-bud axis) or incorrect (see [Figure 1B](#fig1){ref-type="fig"}, left).

This analysis revealed that eight mutants exhibited varying degrees of spindle positioning defects that significantly differed from wild-type ([Figure 1B](#fig1){ref-type="fig"}, right). All of those mutants with defects were those with substitutions in the motor domain, which encompasses the six AAA ([A]{.ul}TPase [a]{.ul}ssociated with various cellular [a]{.ul}ctivities) domains, the linker element that performs the powerstroke, and the microtubule-binding domain (MTBD). All but one of the motor domain mutations led to significant defects. Seven out of the nine mutations linked to malformations in cortical development (MCD) were among those with defects in this assay, whereas none of the mutations associated with the other neurological diseases exhibited significant defects. Although most of these mutants differed to a small but significant degree from wild-type, H3639P exhibited defects as severe as loss of *DYN1* (*dyn1*∆).

Spindle tracking in live cells provides a sensitive readout for dynein-dynactin dysfunction {#s2-2}
-------------------------------------------------------------------------------------------

Given the somewhat binary nature of the spindle positioning assay, it provides only a coarse assessment of mutant functionality. Thus, as a more sensitive readout of mutant dynein function, we imaged dynein-mediated spindle movements in yeast cells and quantitatively assessed various parameters of these movements. Given the reliance of dynein on dynactin for this activity in cells, assessment of spindle movements is in fact a read-out of dynein-dynactin activity. To ensure that spindle translocation events were a consequence of dynein-dynactin activity, we performed these assays in cells deleted for *KAR9*, a genetic component of a pathway that promotes orientation of the spindle along the mother-bud axis ([@bib101]; [@bib31]; [@bib46]) (see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Moreover, we treated these cells with hydroxyurea (HU), an inhibitor of DNA synthesis that arrests yeast in a prometaphase-like state that precludes anaphase onset. This relatively simple but sensitive assay permits detection of subtle defects (or enhancements) in the motility parameters of dynein-dynactin ([@bib58]). In addition to obtaining velocity and displacement values, this assay also provides a readout for relative activity (*i.e.*, how active dynein-dynactin is within the cell). Moreover, by scoring for 'neck transit' success frequency -- events in which a dynein-dynactin-mediated spindle translocation results in successfully transiting the narrow mother-bud neck -- we are also able to determine if there are potential defects in force production. Previous studies have shown that neck transits are compromised in cases where dynein's microtubule-binding affinity is weakened ([@bib14]), or when the CAP-gly domain of Nip100 (homolog of human p150 component of the dynactin complex) is genetically ablated ([@bib58]). Subsequent to HU arrest, full Z-stacks of the mitotic spindle and astral microtubules (via GFP-Tub1) were acquired every 10 s (see [Figure 2A](#fig2){ref-type="fig"} for example), and the position of the spindle was subsequently tracked using a combination of manual (*e.g.*, to assess neck transit success) and automated 3-dimensional tracking (using a custom written Matlab-based routine).

![Quantitative assessment of dynein-dynactin-mediated spindle dynamics reveals refined insight into mutant dysfunction.\
(**A**) Cartoon and representative time-lapse inverse fluorescence images of a hydroxyurea (HU)-arrested *kar9*∆ cell exhibiting typical dynein-mediated spindle movements, analysis of which is presented in panels (**B -- F**). Maximum intensity (X-Y projection; top) and Y-Z projections (bottom) are shown for each time point (NT, neck transit; note, line spans time frames over which the NT occurs). (**B -- F**) Plots of indicated parameters for spindle dynamics in haploid wild-type and mutant strains. Briefly, the mitotic spindles were tracked in 3-dimensions using a custom written Matlab code. Dynein-mediated spindle movements were manually selected from the tracking data, from which velocity (**B**), displacement (**C**, per event; or, **E**, per minute), and the number of dynein-mediated spindle movements per minute (**F**) were obtained. The fraction of successful neck transits (successful attempts divided by total attempts) were manually scored (*i.o.*, insufficient observations; for H3639P, only one unsuccessful neck transit attempt was observed). Each bar represents the weighted mean ± weighted standard error (or standard error of proportion for **D**; n = 42 to 60 HU-arrested cells from three independent experiments were analyzed for each strain; diamonds represent mean values obtained from each independent replicate experiment). Statistical significance was determined using an unpaired Welch's t test (**B and E**), a Mann-Whitney test (**C**), or by calculating Z scores (**D and F**; \*, p≤0.1; \*\*, p≤0.05; \*\*\*, p≤0.005). Also see [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}, [2](#fig2s2){ref-type="fig"}, [3](#fig2s3){ref-type="fig"} and [4](#fig2s4){ref-type="fig"}, and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.010Figure 2---source data 1.Spreadsheet with spindle dynamics assay values for haploid cells.](elife-47246-fig2){#fig2}

This analysis revealed a broader more nuanced array of defects in our library of mutants ([Figure 2B--F](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 2A and B](#fig2s2){ref-type="fig"}). Strikingly, all mutants exhibited varying degrees of alterations in their motility parameters with respect to wild-type cells. At the most severe end of the spectrum, H3639P cells -- which also had the most severe spindle positioning phenotype -- exhibited only 10 dynein-mediated spindle displacement events from all cells observed (compare to a mean of 244 events for all other strains; see [Figure 2---figure supplement 2A and B](#fig2s2){ref-type="fig"} for scatter plots illustrating density of datasets). Consequently, this mutant had extremely low 'activity' parameters (*i.e.*, total spindle displacement, [Figure 2E](#fig2){ref-type="fig"}; and, number of dynein-mediated spindle movements per minute, [Figure 2F](#fig2){ref-type="fig"}). The mutant with the second most severe spindle positioning phenotype, R1852C, exhibited significant defects in all motility metrics, including velocity, displacement (per event), neck transit success, and the two activity parameters. The relative phenotypic severity of these two mutants is consistent with findings from another group in which disease-correlated dynein mutants were assessed using recombinant human dynein complexes ([@bib25]). This group identified the human equivalents of R1852C (R1962C) and H3639P (H3822P) as being the most severe loss-of-function mutants in their reconstituted motility assays (see Discussion).

Another noteworthy mutant was K1475Q, a substitution within the linker domain, the mechanical element that is responsible for the powerstroke ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). This mutation led to a reduction in spindle velocity, displacement, and also reduced the activity metrics of the motor. Given the position of this mutation, it may affect dynein activity by compromising linker remodeling during the priming or powerstroke movement of the linker. However, a recent study identified the equivalent human residue (R1567) as being at least partly required for the formation of an autoinhibited conformation of human dynein called the phi-particle ([@bib102]) (due to its resemblance to the Greek letter; [@bib2]), thus raising the possibility that yeast dynein also adopts this conformation. Thus, the altered motility of this mutant may be a consequence of altered activity regulation (see below and Discussion).

All three mutations within the AAA3 module of the motor domain led to varying degrees of spindle motility alterations (D2439K, R2543K, and L2557M; [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Interestingly, the most striking defect we observed with L2557M was a reduction in the neck transit success rate ([Figure 2D](#fig2){ref-type="fig"}), which is the likely cause of the spindle positioning defect. This suggests that this mutation -- which is buried within the large subdomain of AAA3, and makes hydrophobic contacts with a closely apposed helix -- is likely affecting force generation by the motor.

All three microtubule-binding domain (MTBD) mutants exhibited fairly similar degrees and types of defects in effecting spindle movements (reductions in velocity, displacement, and neck transit success). Structural analysis revealed that all three mutations mapped to the surface of the MTBD that makes contacts with the microtubule ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Given all three substitutions lead to loss of a positive charge, it is likely that these mutations each lead to a reduction in the affinity of the motor for the negatively charged surface of the microtubule. The reduced activity metrics for R3152N and R3201N could thus be a reflection of a reduction in association kinetics of the mutants for the microtubule. This is supported by a study that found reduced microtubule binding for similar amino acid substitutions in a mouse dynein MTBD fragment ([@bib64]).

Although none of them led to significant spindle positioning defects, all of the tail domain mutations led to altered spindle motility parameters. Structural analysis revealed that most of these mutations (7 out of the 8) clustered to two distinct regions: (1) adjacent to, or within the N-terminal dimerization domain, or (2) at a surface that interfaces with the intermediate chain of a neighboring heavy chain in a two dynein:1 dynactin complex ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). This latter region was recently identified as being important to stabilize the binding of a second dynein complex to dynactin, and ensuring that all four heavy chains are properly aligned for efficient motility of the human dynein-dynactin complex ([@bib90]). Our data suggest that the ability to recruit two dynein complexes to dynactin is conserved in yeast, and that disrupting this complex can compromise force generation ([Figure 2D](#fig2){ref-type="fig"}) or activity ([Figure 2E and F](#fig2){ref-type="fig"}). Although the last tail domain mutation, W612C, is in close proximity to this latter region, it is sufficiently far from the contact point with the second dynein complex to suggest that it is likely affecting some other facet of dynein-dynactin function.

Mutations exert dominant negative effects on spindle dynamics {#s2-3}
-------------------------------------------------------------

Given the heterozygous nature of these mutations in affected patients, we wondered how the mutants would behave in the presence of a second, wild-type copy of dynein. It is currently unclear whether cells with two copies of *DYN1* (*e.g.*, wild-type and mutant) assemble dynein complexes comprised of two different copies (*e.g.*, wild-type/mutant heterodimers), or whether they are comprised of only one copy (*e.g.*, wild-type homodimers, or mutant homodimers). This latter phenomenon could be a consequence of co-translational dimerization ([@bib59]). To distinguish between these two possibilities, we generated diploid yeast strains that contained one copy of a GFP-tagged dynein heavy chain (*DYN1-GFP*), and a second copy that was fused to an N-terminal affinity tag and a C-terminal HALO tag (*ZZ-DYN1-HALO*), the latter of which could be used to fluorescently label the motor ([Figure 3A](#fig3){ref-type="fig"}). Lysate from these cells was subjected to affinity chromatography, and subsequent to incubation with a red fluorescent HALO ligand (HALO-TMR), the bound protein was eluted and used in a single molecule imaging experiment. If heterodimers assemble within cells, we expected to observe dual-color labeled molecules (green and red); however, if only homodimers form, then we expected to observe only red molecules (see [Figure 3A](#fig3){ref-type="fig"}). Although we observed a small number of motile green molecules (0.9% of the total; likely due to contaminating Dyn1-GFP molecules in the protein preparation), and a single dual labeled molecule (0.3% of the total; [Figure 3B](#fig3){ref-type="fig"}, arrow), the vast majority of motile molecules (98.8%) were exclusively red, indicating that dynein very rarely, if ever, forms heterodimers ([Figure 3C](#fig3){ref-type="fig"}). This suggests a co-translational dimerization model for dynein complex assembly, similar to what has been observed for p53 ([@bib60]).

![Quantitative assessment of spindle dynamics in heterozygous diploid cells reveals dominant nature of mutations.\
(**A**) Schematic depicting experimental approach to determine whether distinct proteins from two different dynein alleles homo- or heterodimerize. (**B and C**) Representative kymograph (**B**) depicting large proportion of red (HALO-tagged) dynein molecules walking along microtubules (only one of which colocalized with a GFP-tagged dynein; arrow), along with associated quantitation (**C**). (**D -- E**) Schematic depicting experimental approach to assess dynein-dynactin activity in heterozygous diploid cells (**D**), and representative inverse fluorescence images of a diploid hydroxyurea (HU)-arrested *kar9*∆/*kar9*∆ cell exhibiting typical dynein-mediated spindle movements. Maximum intensity (X-Y projection; top) and Y-Z projections (bottom) are shown for each time point. (**F -- I**) Plots of indicated parameters for spindle dynamics in indicated diploid yeast strains. Each bar represents the weighted mean ±weighted standard error (or standard error of proportion for I; n ≥ 29 HU-arrested cells from two independent experiments were analyzed for each strain; diamonds represent mean values obtained from each independent replicate experiment). Statistical significance was determined using an unpaired Welch's t test (**F and H**), a Mann-Whitney test (**G**), or by calculating Z scores (**I**). Also see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.013Figure 3---source data 1.Spreadsheet with spindle dynamics assay values for diploid cells.](elife-47246-fig3){#fig3}

Next, we wished to recapitulate the heterozygous nature of some mutations in our budding yeast system. To this end, we chose three mutants -- E545V, R1852C, H3639P -- and determined whether they could affect dynein activity in heterozygous diploid yeast strains. We mated haploid wild-type cells with haploid mutant cells to generate heterozygous diploid cells (*e.g.*, *DYN1*/*dyn1^R1852C^*; [Figure 3D](#fig3){ref-type="fig"}). In addition to comparing dynein activity in these cells to that from homozygous wild-type cells (*i.e.*, *DYN1*/*DYN1*), we also compared them to hemizygous cells with only one copy of *DYN1* (*i.e.*, *DYN1*/*dyn1∆*; [Figure 3E--I](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Although homozygous wild-type cells exhibited similar dynein-dynactin activity to the hemizygotes, the velocity was somewhat reduced in the latter, suggesting a critical concentration of dynein is required for effecting maximal spindle velocity ([Figure 3F](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Analysis of the heterozygous mutants revealed that all three exhibited partial loss-of-function phenotypes in almost all assays with respect to the hemizygous cells, indicating that they are all indeed dominant alleles. Taken together, these data indicate that homodimers of mutant dynein are sufficient to compromise the activity of wild-type homodimers within the cell.

Single molecule motility assays reveal insight into dynein-intrinsic dysfunction {#s2-4}
--------------------------------------------------------------------------------

Findings from our spindle tracking assay revealed the consequences of mutations on various parameters of dynein-dynactin-mediated spindle movements. These movements are mediated by cortically anchored dynein-dynactin complexes that are regulated at various levels by numerous effector molecules (*e.g.*, Pac1, Ndl1, Num1, She1; [@bib52]; [@bib55]; [@bib45]; [@bib37]). For instance, cortical targeting of dynein is affected by various molecules, including Pac1, which tethers dynein to microtubule plus ends ([@bib41]), and Num1, which anchors dynein-dynactin complexes to the cortex ([@bib23]). Thus, mutations that alter the ability of dynein to interact with or be affected by these molecules will result in alterations in dynein-dynactin-mediated spindle movements. To determine whether mutations affect dynein-intrinsic activities, it is therefore important to specifically assess dynein activity without these complicating factors. To this end, we employed a single molecule motility assay, in which the movement of individual purified dynein motors is quantitatively assessed. Performing this assay using yeast dynein has one key advantage over human dynein: unlike human dynein, which requires dynactin and one of several adaptor molecules for processive single molecule motility (*e.g.*, BicD2, Hook3; [@bib56]; [@bib77]), yeast dynein is a processive motor without these factors ([@bib69]). This somewhat unique property of yeast dynein thus permits an unbiased assessment of dynein-intrinsic motility.

Single molecule motility analysis of each mutant revealed that thirteen of those that exhibited defects in the spindle tracking assay showed some degree of motility alteration in the in vitro assay ([Figure 4](#fig4){ref-type="fig"}; see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} for scatter plots and some example kymographs). Interestingly, the precise defect in vivo was not always predictive of the alteration in dynein motility in vitro. Although the reasons for this are unclear, they are likely due in part to the differences in requirements for spindle transport versus those for unloaded single molecule motility (*i.e.*, in which there is no resistance to transport). Additionally, small defects in single motor motility may lead to more pronounced defects in the context of a motor ensemble, as may be the case for dynein at the cell cortex ([@bib51]). Such mutants included W612C and R1852C, both of which led to a reduction in all spindle tracking metrics in cells, but had very little effect on the displacement (run length) of single molecules in vitro. Similarly, R2543K, which reduced spindle velocity by \~50% had only a minor effect on single molecule velocity values.

![Single molecule analysis reveals insight into dynein-intrinsic dysfunction.\
(**A**) Cartoon representation of experimental approach. (**B -- D**) Quantitation of indicated parameters of single molecule motility. Each bar represents the weighted mean ± weighted standard error (or standard error of proportion for D; n ≥ 284 single molecules from at least two experiments from independent protein preparations; diamonds represent mean values obtained from each independent protein preparation). Technical difficulties precluded us from generating the L213I mutant in the yeast strain used for protein purification. Statistical significance was determined using an unpaired Welch's t test (**B**), a Mann-Whitney test (**C**) or by calculating Z scores (**D**; \*, p≤0.1; \*\*, p≤0.05; \*\*\*, p≤0.005). Also see [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}, and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.017Figure 4---source data 1.Spreadsheet with all full-length and minimal GST-dimerized dynein single molecule motility values.](elife-47246-fig4){#fig4}

In a few cases, we observed little or no difference from wild-type in single molecule motility parameters in spite of differences in the spindle tracking assay (*i.e.*, E109I, K540C, E545V, I554M, D2439K, L2557M). In two of these cases (E545V and L2557M), one of these changes was a reduction in the neck transit success rate (see [Figure 2D](#fig2){ref-type="fig"}). As discussed above, this phenomenon is potentially a readout of force generation. Given the unloaded nature of single molecule motility, this assay would be unable to detect differences in force generation by dynein. Although the molecular determinants of dynein force production are not well understood, it is possible that these mutations specifically affect the ability of dynein to remain bound to microtubules under conditions of high load.

Although most mutants exhibited loss-of-function phenotypes in the in vitro assay, a few mutations led to gain-of-functions. For instance, R241L, N283R, and K1475Q all led to an increase in velocity, while K1475Q also caused an increase in run length and a small but significant increase in the fraction of active motors (see [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"} for example kymograph). We confirmed the increased run length for K1475Q was not a consequence of motor aggregates, which could presumably lead to an increase in apparent processivity ([@bib13]) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). As mentioned above, R241 and N283 are adjacent to the N-terminal dimerization domain, and K1475 is within the linker domain (see [Figure 2---figure supplements 3](#fig2s3){ref-type="fig"} and [4](#fig2s4){ref-type="fig"}). In the cases of R241L and N283R, the gain-of-functions observed in vitro are possibly causative of the in vivo deficiencies, indicating that a faster or more processive motor is not advantageous for the spindle positioning function (see below and Discussion regarding K1475Q). This is consistent with recent studies that showed gain-of-functions in dynein (or dynein regulators) can lead to defects in dynein-mediated neuronal maturation ([@bib30]), or spindle orientation ([@bib102]).

In summary, in all cases in which motility parameters were altered in vitro as a consequence of a particular mutation, we are able to conclude that the underlying molecular defect is most likely intrinsic to dynein itself, and is likely not a consequence of an altered interaction with either accessories or regulators.

Localization phenotypes provide mechanistic basis for dysfunction in a subset of mutants {#s2-5}
----------------------------------------------------------------------------------------

Our in vivo and in vitro functional data described above revealed the particular parameters of dynein motility that were altered by the mutations, and also whether the altered motility was in fact intrinsic to dynein (*i.e.*, if there was an in vitro phenotype), or was possibly a consequence of alterations in interactions with regulators such as dynactin. As discussed above, proper dynein function in yeast relies on the coordinated action of various molecules to localize dynein to microtubule plus ends, from where it is offloaded to its site of action: the cell cortex ([Figure 5A](#fig5){ref-type="fig"}) ([@bib55]). For instance, dynein plus end localization occurs in a dynactin-independent manner ([@bib57]), but requires an interaction with Pac1 (the LIS1 homolog) ([@bib41]), as well as the accessory chains Dyn3 ([@bib54]) (light-intermediate chain) and Pac11 (intermediate chain) ([@bib42]). In contrast, dynactin is required for dynein to localize to cortical Num1 receptor sites ([@bib57]). Thus, quantitative assessment of dynein localization can reveal potentially altered interactions with various regulators or accessories.

![Quantitative assessment of dynein localization reveals potential basis for mutant dysfunction.\
(**A**) Cartoon representation depicting the two main sites of dynein localization, and the molecular basis for each. Dynein plus end localization (1) requires Bik1, Pac1, and possibly Bim1, but does not require dynactin. Rather, dynactin plus end localization (2) relies on dynein. Association of dynein with the cortex (3) requires dynactin and the cortical receptor, Num1. (**B**) The frequency of dynein localization to either microtubule plus ends or the cell cortex is plotted for indicated strains. To enrich for mitotic cells, overnight cultures were diluted into fresh media for 1.5 hr prior to imaging. To further reduce variability due to cell cycle-dependent changes ([@bib50]), localization frequency was scored for mitotic cells only. Each data point represents the weighted mean ± weighted standard error (68 to 111 mitotic cells from at least two independent experiments were analyzed for each strain). (**C and D**) Fluorescence intensity values for either plus end (**C**) or cortical (**D**) dynein foci observed in mitotic cells described in B (4 to 59 plus end foci, and 4 to 22 cortical foci from two independent experiments were analyzed; *i.o.*, insufficient observations; only one cortical focus was observed for both R1852C and H3639P). Statistical significance was determined by calculating Z scores (**B**), or by applying an unpaired Welch's t test (**C and D**; \*, p≤0.1; \*\*, p≤0.05; \*\*\*, p≤0.005). Also see [Figure 5---figure supplements 1](#fig5s1){ref-type="fig"} and [2](#fig5s2){ref-type="fig"}, and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.021Figure 5---source data 1.Spreadsheet with localization frequency and intensity values for wild-type and mutant Dyn1-3GFP.](elife-47246-fig5){#fig5}

For this analysis, we focused on a select group of mutants: those with substitutions within the N-terminal tail domain (which is the site for interaction with the accessory chains, dynactin, and Num1; [@bib50]), those with the most severe phenotypes (R1852C, R2543K, and H3639P), and two of the MTBD mutants. We acquired time-lapse images of haploid cells expressing fluorescently-labeled tubulin (mRuby2-Tub1; α-tubulin) and 3GFP-tagged copies of each dynein mutant. Plus end and cortical foci were identified from movies, and their targeting frequency (*i.e.*, percent cells with foci) and fluorescence intensities (a readout of molecule number per site) were quantified.

This analysis revealed significantly altered localization frequencies or intensities for most of the mutants, including L213I, N283R, E545V, I554M, W612C, K1475Q, R1852C, R2543K, and H3639P ([Figure 5B--D](#fig5){ref-type="fig"}). For instance, the K1475Q substitution (within the linker) led to a large increase in the frequency of observing cortical foci (2.2-fold; p=0.0011), but a concomitant reduction in the number of molecules per cortical focus (38% reduction in fluorescence intensity; p=0.0117), whereas W612C, R1852C and H3639P all exhibited a reduction in dynein levels at plus end and cortical sites (see Discussion). Finally, immunoblotting revealed that protein expression differences likely do not account for the observed localization or activity phenotypes ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

The increased frequency of cortical foci for K1475Q suggests that this mutant may exhibit higher affinity for Pac1 and/or dynactin, the former of which is limiting for plus end association, and the latter of which is limiting for offloading to cortical Num1 sites ([@bib51]). Given the importance of the human equivalent of K1475 (R1567) in stabilizing the autoinhibited 'phi' particle conformation -- which exhibits lower affinity for dynactin than the open, uninhibited state ([@bib102]) -- we wondered whether K1475Q interacts more readily with dynactin. To address this, we measured the relative ratio of dynein (using Dyn1-3GFP) to dynactin (Jnm1-3mCherry, homolog of p50/dynamitin) at microtubule plus ends, where dynactin recruitment is wholly dependent on dynein ([@bib57]). Since assembled dynein-dynactin complexes are readily offloaded to cortical Num1 receptor sites ([@bib55]), we chose to perform this analysis in cells lacking Num1 (*num1∆*) to exclude any contribution from the offloading process to the relative ratio of dynein to dynactin at plus ends ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Interestingly, this analysis indeed revealed a significantly increased ratio of dynactin to dynein at plus ends ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}; from a mean of 1.07 to 1.52; p\<0.0001), indicating that K1475Q interacts more readily with dynactin than wild-type dynein, and that this mutation may in fact be disrupting a potential autoinhibited state of yeast dynein.

Proline-dependent structural constraint is the likely cause for dysfunction in dynein H3639P {#s2-6}
--------------------------------------------------------------------------------------------

Given the wealth of structural information currently available for dynein, we sought to determine the structural basis for dysfunction in two of the mutants: R1852C and H3639P. Analysis of available dynein structures revealed that H3639 is situated within a conserved loop that connects two alpha helices, one of which is an extension of the buttress, a structural element that helps to communicate nucleotide-dependent structural rearrangements within the AAA ring to the MTBD ([Figure 6A](#fig6){ref-type="fig"}) ([@bib78]). We first asked whether gain of proline or loss of histidine is the cause for the severe loss-of-function. To this end, we substituted H3639 with either a serine (to preserve the polar nature and hydrogen-bonding capabilities of histidine), valine (a hydrophobic residue), or asparagine (found in the equivalent position of human dynein-2), and assessed the activity of these mutants in the spindle positioning assay. None of these substitutions led to significant spindle positioning defects, indicating that gain of proline is the reason for dynein dysfunction in H3639P ([Figure 6B](#fig6){ref-type="fig"}). We next asked if proline substitutions are tolerated at other sites within this inter-helical loop. Using the spindle positioning assay, we found that proline was well tolerated at all sites within the inter-helical loop except for position 3641 (2 residues C-terminal to 3639; [Figure 6B](#fig6){ref-type="fig"}). Thus, introduction of a proline at two distinct sites within this loop are sufficient to severely compromise dynein function.

![Detailed dissection of the molecular basis for dysfunction in H3639P.\
(**A**) Color-coded structural model of the dynein motor domain (from PDB 4RH7; [@bib78]) with zoomed in region depicting H3639 residing within an inter-helical loop within AAA5. (**B**) Fraction of cells with mispositioned spindles are plotted for yeast strains with indicated dynein mutations. Each data point represents the fraction of mispositioned anaphase spindles along with standard error (weighted mean ± weighted standard error of proportion; n ≥ 67 anaphase spindles from at least two independent experiments for each strain; \*\*\*, p≤0.0001). (**C**) Representative time-lapse inverse fluorescence images of two hydroxyurea (HU)-arrested *kar9*∆ cells with indicated dynein mutations. Note the lack of spindle translocation in H3639P, but the clear dynein-mediated movement in the F3638G H3639P W3640G mutant (dashed lines provide a point of reference). Maximum intensity projections are shown for each time point. (**D -- E**) Plots of two activity parameters for spindle dynamics in indicated haploid strains (total displacement, **D**; and, number of events per minute, **E**). Each data point represents the weighted mean ± weighted standard error (**D**) or standard error of proportion (E; n ≥ 29 HU-arrested cells from at least two independent experiments were analyzed for each strain). (**F and G**) The frequency of dynein localization to either microtubule plus ends, the cell cortex, or spindle pole bodies (SPBs) is plotted for indicated strains and drug treatment (for mitotic cells only). In addition to the indicated alleles and drug treatment, the plot in panel **G** depicts cells that possess the *prd1-DBD-CYC8* allele, which represses transcription of pleiotropic drug resistance genes ([@bib84]), thus promoting intracellular retention of MG132. These cells were treated with 75 µM MG132 for 1.5 hr prior to imaging (control cells were treated with an equal volume of DMSO). Each data point represents the weighted mean ± weighted standard error (73 to 107 mitotic cells from two independent experiments were analyzed for each strain). Statistical significance was determined by calculating Z scores (**B, E, F and G**), or by applying an unpaired t-test with Welch's correction (**D**). Also see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Figure 6---source datas 1](#fig6sdata1){ref-type="supplementary-material"} and [2](#fig6sdata2){ref-type="supplementary-material"}, and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.024Figure 6---source data 1.Spreadsheet with spindle dynamics assay values for inter-helical loop mutants.\
10.7554/eLife.47246.025Figure 6---source data 2.Spreadsheet with localization frequency values for wild-type and mutant Dyn1-3GFP in the absence and presence of MG132.](elife-47246-fig6){#fig6}

We hypothesized that prolines are not tolerated in these two regions (residues 3639 and 3641) of the inter-helical loop because of the structural constraints imposed by prolines due to bond angle restrictions. If this were true, then we reasoned that increasing the structural flexibility in the immediate vicinity of P3639 might rescue the proline-dependent defects. To test this, we introduced glycine substitutions at either the N-terminal residue (F3638), the C-terminal residue (W3640), or both. For reasons that are unclear, both double mutants (*i.e.*, F3638G H3639P, and H3639P W3640G) led to spindle positioning defects that were significantly more severe than H3639P and dynein knock-out cells (*dyn1∆*; p\<0.0001; [Figure 6B](#fig6){ref-type="fig"}). Strikingly, however, the triple mutant -- in which P3639 is flanked by glycines (*i.e.*, F3638G H3639P W3640G) -- exhibited spindle positioning defects that were significantly less severe than H3639P (p\<0.0001).

To confirm these findings, we assessed the activity of the triple mutant using the spindle tracking assay. Although the activity of this mutant was much less than that of wild-type dynein-expressing cells, it was significantly greater than the H3639P single mutant (p≤0.0361; [Figure 6C--E](#fig6){ref-type="fig"}). In spite of the increase in activity, the quality of the spindle movements (velocity and displacement per event) were nearly identical between H3639P and the triple mutant ([Figure 6---figure supplement 1A--D](#fig6s1){ref-type="fig"}). Interestingly, the single molecule assay revealed that the triple mutant was no better than the single mutant in any metrics ([Figure 6---figure supplement 1E--I](#fig6s1){ref-type="fig"}). This indicates that the triple mutant does not rescue dynein motility, but some other metric of in vivo dynein (or dynein-dynactin) activity. We next performed live cell imaging to determine if the triple mutant alters any aspects of dynein localization. Although the flanking glycines did not rescue plus end or cortical localization, it did lead to a large increase in the fraction of cells exhibiting dynein foci at the spindle pole bodies (SPBs; [Figure 6F](#fig6){ref-type="fig"}; p\<0.0001), suggesting that the triple mutant shifts the balance toward more semi-active -- or properly folded -- dynein within cells with respect to the single H3639P. The relevance of dynein localization to the SPB is unclear, but previous work from our lab demonstrate that this localization requires the MTBD ([@bib37]). In light of our other observations, the increased localization frequency of the triple mutant suggests that the flanking glycines rescue H3639P cellular defects by reducing proline-dependent inflexibility, which in turn may prevent global misfolding of Dyn1, thus increasing the relative concentration of active dynein within the cell. If H3639P causes some fraction of Dyn1 to be misfolded within the cell, then we reasoned that increasing the total amount of protein in cells would lead to an increase in the number of active Dyn1 molecules, and thus an increase in the apparent degree of H3639P localization. To test this, we assessed dynein localization in the absence or presence of MG132, a proteasome inhibitor, addition of which would lead to an increase in total protein content, including dynein. Addition of MG132 increased the frequency of wild-type cortical dynein foci by approximately 2-fold (p=0.0013), but had no significant effect on the frequency of either SPB or plus end targeting ([Figure 6G](#fig6){ref-type="fig"}). Consistent with our hypothesis, MG132 treatment increased the frequency of plus end targeting of H3639P by 3.7-fold (p\<0.0001) to levels comparable to wild-type dynein; however, the frequency of cortical targeting of H3639P was unaffected by proteasome inhibition.

An ectopic disulfide bond is the likely cause for R1852C dysfunction {#s2-7}
--------------------------------------------------------------------

Close inspection revealed a cysteine situated within very close proximity to R1852 (\~3 Å; [Figure 7A](#fig7){ref-type="fig"}), which lies within the first AAA module (AAA1). Given the mutation results in a cysteine substitution at this site, we reasoned that an ectopic disulfide bond may be responsible for the phenotypic consequences. To determine whether this was the case, we mutated the closely apposed, highly conserved cysteine to a serine (C1822S; [Figure 7B](#fig7){ref-type="fig"}), which would eliminate the potential for disulfide bond formation at this site. We then used several of our assays to quantitate the degree to which C1822S might rescue defects due to R1852C.

![Detailed dissection of the molecular basis for dysfunction in R1852C.\
(**A**) Color-coded structural model of the dynein motor domain (from PDB 4RH7; [@bib78]) with zoomed in region depicting R1852 residing within AAA1 near its interface with AAA2. (**B**) Sequence alignment illustrating the high degree of conservation for C1822 (yellow star) and R1852 (red star) among various dynein heavy chains. (**C and D**) Plots of two activity parameters for spindle dynamics in indicated haploid strains (total displacement, **C**; and, fraction of successful neck transits, **D**). Each data point represents the weighted mean ± weighted standard error (**C**) or standard error of proportion (D; n ≥ 28 HU-arrested cells from two independent experiments were analyzed for each strain). (**E**) Plot of velocity values for single molecules of indicated GST-dynein~331~ variants (n ≥ 158 single molecules from at least two independent experiments were analyzed for each motor variant). (**F**) Representative fields of microtubules being translocated by surface-adsorbed recombinant human dynein complexes. (**G and H**) Plots depicting velocity (**G**) and fraction (**H**) of microtubules (at least 50 microtubules from two independent experiments were analyzed for each variant; '*n.o.*", none observed). Statistical significance was determined by calculating Z scores (**B and E**), or by applying an unpaired Welch's t test (**D**). Also see [Figure 7---figure supplements 1](#fig7s1){ref-type="fig"} and [2](#fig7s2){ref-type="fig"}, [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}, and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.47246.029Figure 7---source data 1.Spreadsheet with spindle dynamics assay values for R1852C related mutants.](elife-47246-fig7){#fig7}

Although C1822S alone compromised all parameters of dynein-dynactin-mediated spindle movements, this substitution led to a partial restoration of most of the parameters in the R1852C mutant (*i.e.*, C1822S R1852C double mutant; [Figure 7C and D](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). We observed a similar restoration of function in a C1822A R1852C double mutant. We ruled out the possibility that the partially hydrophobic nature of cysteine is the cause for the dysfunction in R1852C by assessing an R1852V mutant, which exhibited defects that were significantly less severe than R1852C. Moreover, combining C1822S with R1852V led to no degree of rescue with respect to the single R1852V mutant, which is in stark contrast to our observations with the double C1822S R1852C mutant ([Figure 7C and D](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). We also found that C1822S rescued the localization of R1852C to plus ends and the cell cortex almost to wild-type levels ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). As with the spindle tracking assay, although R1852V led to localization defects, the C1822S R1852V double mutant was almost identical to R1852V alone.

Before assessing the extent of rescue with the single molecule assay, we first tested whether using a minimal dynein fragment that is sufficient for processive motility ([@bib69]) would rescue any of the motility defects we observed with the R1852C mutant (GST-dynein~331~). This fragment -- a glutathione S-transferase (GST)-dimerized motor domain that exhibits motility parameters that are very similar to the full-length molecule ([@bib69]) -- lacks the tail domain, and thus does not co-purify with or rely on any of the accessory chains. If protein misfolding is partly to blame for mutant dysfunction -- as suggested from the single molecule (only 23.2% active motors; [Figure 4D](#fig4){ref-type="fig"}) and localization assays (severe reduction in localization frequency; [Figure 5B](#fig5){ref-type="fig"}) -- then we reasoned that the simplicity and compact fold of GST-dynein~331~ might rescue some of these defects. In striking contrast to the full-length mutant, the fraction of active GST-dynein~331~ R1852C motors was almost identical to that of the wild-type GST-dynein~331~ motor (note the same construct did not rescue the H3639P mutant; [Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}), suggesting that the holoenzyme complex is more susceptible to defects arising from this mutation than is the truncated motor domain. However, much like the full-length molecule, the velocity of the GST-dynein~331~ mutant was severely reduced with respect to wild-type ([Figure 7E](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1G](#fig7s1){ref-type="fig"}). Consistent with the spindle tracking data, C1822S was indeed sufficient to significantly rescue the single molecule velocity defect in the minimal dynein fragment ([Figure 7E](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1G](#fig7s1){ref-type="fig"}). Taken together, these findings indicate that an ectopic disulfide bond is the likely cause for R1852C dysfunction.

Compensatory mutation partially suppresses motility defects of human dynein mutant {#s2-8}
----------------------------------------------------------------------------------

Finally, we sought to determine whether the compensatory cysteine to serine substitution would also rescue motility defects in human dynein. To this end, we engineered the equivalent mutations (C1932S, R1962C, or C1932S R1962C) into an insect cell expression plasmid encoding an affinity-tagged human dynein complex (ZZ-SNAPf-DYNC1H1, IC2, LIC2, Tctex1, Robl1, LC8; a kind gift from Andrew Carter). Subsequent to purification of recombinant complexes, we assessed their function using a microtubule gliding assay in which free microtubules are translocated by dynein complexes non-specifically adsorbed to the glass surface. This assay permits an assessment of dynein-intrinsic motility parameters without the need for additional factors that are required for single molecule motility of human dynein (*i.e.*, dynactin and a requisite adaptor \[[@bib56]; [@bib77]\]). Consistent with previous findings, the single R1962C mutation (equivalent to R1852C) was sufficient to completely disrupt microtubule gliding activity ([@bib25]) ([Figure 7F--H](#fig7){ref-type="fig"}); however, as with yeast dynein, substitution of the closely apposed cysteine to a serine (C1932S) was sufficient to restore some of the lost function. Although the compensatory mutation did not restore activity to wild-type levels (note the low velocity and degree of activity with respect to wild-type in [Figure 7G and H](#fig7){ref-type="fig"}), the same was true for the full-length yeast dynein complex, which was only partially rescued by the mutation (see [Figure 7C and D](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). Although unclear, the different degrees of rescue by the compensatory mutation with yeast dynein (observed in vivo; [Figure 7C and D](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A--D](#fig7s1){ref-type="fig"}) versus human dynein (observed in vitro; Fig. F-H) may be due to the presence of quality control mechanisms at play in live yeast cells which ensure that mostly properly folded motors are delivered to cortical receptor sites. No such mechanism is present to prevent adsorption of inactive recombinantly produced human dynein motors to the glass in the in vitro gliding assay. In summary, these results confirm our findings with yeast dynein, and moreover validates yeast as a powerful model system to understand the molecular basis for dynein dysfunction in patients.

Severity of dynein dysfunction correlates with disease type {#s2-9}
-----------------------------------------------------------

In an effort to identify potential correlations between degree of dynein dysfunction and disease, we summarized the findings from all of our various assessments into a heat map in which the variance (or lack thereof) from wild-type was assigned a color based on the statistical significance (*e.g.*, green, p≥0.100; red, p≤0.005; [Figure 8A](#fig8){ref-type="fig"}). Unsurprisingly, on average, mutations within the highly conserved motor domain exhibited more statistically significant differences from wild-type than those in the tail domain. Moreover, this broad view of dysfunction in the mutant library revealed that the more severe loss-of-function mutants appeared to correlate with MCD, while those with lesser defects mainly correlate with motor neuron diseases (SMA-LED, CMT or CMD).

![Summary of phenotypic analysis of disease-correlated mutants.\
(**A**) Heat map depicting degree of statistical significance for difference between each mutant and wild-type cells for the indicated assays (SP, spindle positioning; V, velocity; D, displacement per event; A, activity; NT, neck transit; L, localization; %A, percent active motors; MCD, malformations in cortical development; CMT, Charcot-Marie-Tooth disease; SMA-LED, spinal muscular atrophy with lower extremity dominance; CMD, congenital muscular dystrophy). Red asterisks depict mutants that were assessed in a previous study using recombinant human dynein ([@bib25]). ‡Note that we mistakenly substituted an asparagine for residue R3201 instead of a glutamine, the latter of which was identified as correlating with MCD ([@bib64]). R3201N was used throughout this study. Deviation from wild-type cells in either the 'total spindle displacement' (see [Figure 2E](#fig2){ref-type="fig"}), or the 'number of dynein-mediated spindle movements per minute' (see [Figure 2F](#fig2){ref-type="fig"}) metric was used for the activity column ('A'). Mutants are listed from N- to C-terminus of Dyn1 (shading indicates in which domain of Dyn1 each mutation resides). Significance was calculated as indicated in previous figure legends. (**B**) Each mutant ranked by their coefficient of dynein dysfunction score (CDD; see text and [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). As shown, above a CDD score of \~ 18, the correlation with malformations in cortical development increases, while that with motor neuron diseases decreases. Also see [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}.](elife-47246-fig8){#fig8}

To more quantitatively assess our data for potential correlations between dynein dysfunction and disease type, we developed a system in which the degrees of variance from wild-type for each mutant were assigned numerical scores that we then used to tabulate a single value that represents the degree of dynein dysfunction for each mutation (coefficient of dynein dysfunction, or CDD). For tabulation of the CDD value, we focused on the in vivo data only. The reasons for this were two-fold: (1) defects observed in the in vivo assays were largely reflective of the degree of dysfunction, whereas the in vitro data generally revealed the mechanisms of dysfunction (*e.g.*, whether the mutation affected dynein-intrinsic or extrinsic function); and, (2) all mutants with in vivo defects also exhibited in vitro defects, and so we chose to include only the in vivo data to avoid redundancies in the CDD tabulation. In addition to the spindle positioning assay, values from the following spindle dynamics metrics were used to compile the CDD: velocity, displacement per event, neck transit success rate, total spindle displacement per minute, and number of events per minute. The latter two were both included in the CDD tabulation since they revealed two different aspects of dynein activity: the extent to which the mutant dynein-dynactin complexes could move the spindle (total displacement per minute), and the ability to initiate a spindle movement event (number of events per minute). Since the spindle positioning assay reveals gross perturbations in dynein function, we increased the weight of this score with respect to each of the other metrics, such that the summed spindle dynamics metrics were weighed equally with that of the spindle positioning assay (see [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} for additional details on CDD tabulation). This analysis revealed a broad range of dynein dysfunction ranging from low (\<10) to high CDDs (\>30) for the mutant library. For comparison, the CDDs for wild-type and *dyn1*∆ cells were set to 0 and 100, respectively. Thus, considering the phenotypic severity of H3639P (CDD = 82) -- which had a spindle positioning defect as severe as *dyn1*∆, but exhibited some dynein activity in the spindle dynamics assays -- we find that the CDD score accurately reflects the degree of dysfunction for each mutant.

Ranking the mutants according to their CDD scores (from low to high; [Figure 8B](#fig8){ref-type="fig"}) revealed an apparent correlation between dynein dysfunction and disease type. Specifically, we found that above a CDD value of \~ 18, the likelihood of the mutation correlating with MCD increased, while its correlation with SMA-LED, CMT or CMD decreased. This suggests that the two general types of diseases (motor neuron disease, and defects in brain development) are each caused by different degrees of dynein dysfunction, and that there exists a lower threshold of dynein activity that is required for neurological development (see Discussion).

Discussion {#s3}
==========

Neurodegenerative or developmental diseases that arise as a consequence of mutations within the dynein gene -- or dyneinopathies -- are a broad range of devastating diseases that include muscular atrophy, muscular dystrophy, and malformations in cortical development (MCD). The ages of onset for these diseases range from birth to late adulthood, while the severity of the symptoms associated with them also cover a broad range ([@bib64]; [@bib39]; [@bib96]; [@bib92]). Although the underlying reasons behind this symptomatic diversity are unclear, our findings suggest that the degree of dysfunction is at least a potential genetic determinant of the type of disease. Specifically, motor neuron diseases appear to be more susceptible to even small degrees of dysfunction (CDD from 5 to 18), while MCD tends to correlate with larger degrees of dynein dysfunction (CDD ≥ 19). The reasons for this are unclear, but we hypothesize that the differences are due to the somewhat distinct types of dynein-mediated transport required to maintain motor neuron health, versus that required to effect nuclear or neuronal migration in the developing neocortex. Motor neurons possess extremely long axons (≤1 m), and thus require a high degree of processive transport for the myriad vesicular cargoes that are moved from the soma to the axon terminal and back. This transport takes place not only during development and in growing children, but also in fully matured adults. Thus, it stands to reason that even subtle loss-of-functions in dynein-mediated transport can, over time, compromise motor neuron health. This is apparent from the wide range in ages-of-onset (from birth to adulthood), and in the range of severity for dynein-based motor neuron diseases (from weakness in the lower limbs to gross motor difficulties). On the other hand, during early brain development, dynein plays key roles in interkinetic nuclear migration (INM) and neuronal migration during development of the neocortex ([@bib87]; [@bib28]; [@bib86]). Nuclear envelope-anchored dyneins move the nucleus tens of microns from the basal to the apical surface of the neuroepithelium ([@bib28]). In addition to being a shorter distance traveled compared to axonal transport in a motor neuron, the number of motors engaged with microtubules during a nuclear migration event is likely far greater. Immunofluorescence reveals dynein is present along most of the nuclear envelope surface ([@bib28]). Moreover, live cell imaging revealed that the microtubule network is fairly extensive in the proximity of the nucleus ([@bib87]; [@bib86]). A similar process may be at play during post-INM neuronal migration, when dynein assists in centrosome advancement of the postmitotic neuron. Evidence suggests that, as in budding yeast, astral microtubules make contacts with teams of cortically anchored dynein motors to move the centrosome ([@bib86]). Thus, for both INM and neuronal migration, many dynein molecules are likely engaging with microtubules to effect neurogenesis. This is in contrast to a vesicle that is being transported along the axon of a motor neuron, which likely possesses far fewer motors (\~3--7 per vesicle \[[@bib24]; [@bib66]\]), of which potentially only a subset are engaged due to the geometric constraints associated with a three-dimensional vesicle engaging with a single filament. Thus, the minimal functional requirements for individual dynein motors during INM or neuronal migration are potentially lower due to the large number of motors engaged during a migration event. In such a scenario, teams of motors comprised of a mixture of wild-type and mutant variants (due to the heterozygous nature of these diseases) can work together to effect INM, but are less able to effectively transport single vesicular cargoes along the axon.

Our data indicate that K1475Q -- a mutation in the linker domain -- increases dynein run length in vitro, and alters its localization pattern in vivo. The position of this mutation (at an intermolecular interface that helps mediate formation of an autoinhibited Phi particle conformation of human dynein; [@bib102]) suggests that the associated phenotypes may be a consequence of altered activity regulation. Given this mutant exhibited dynein-intrinsic enhancements in in vitro activity, the reduction in cellular dynein-dynactin activity is likely a consequence of the altered localization pattern. Specifically, the localization phenotype raises the possibility that a reduction in the number of dynein-dynactin complexes per cortical site (as apparent by the reduced fluorescence intensity of cortical foci; [Figure 5D](#fig5){ref-type="fig"}) -- which would result in fewer motor complexes being engaged for a spindle movement event -- is the basis for cellular dysfunction. Given the autoinhibited Phi particle exhibits reduced affinity for dynactin ([@bib102]), the altered localization pattern of the mutant may be due to disruption of a similar autoinhibitory conformation in yeast, consequent increased dynactin binding -- which is supported by our ratiometric fluorescence imaging ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) -- and thus an increase in the frequency of cortical off-loading events ([@bib55]). Previous studies have suggested that dynein's interaction with dynactin is a limiting step in the delivery of dynein-dynactin complexes to cortical Num1 sites ([@bib51]). We are currently focused on assessing whether yeast dynein indeed adopts such an autoinhibited state, and what role this conformation plays in the regulation of dynein activity.

In addition to revealing the potential molecular basis for disease onset or progression in affected patients, our findings also identified the potential structural basis for dynein dysfunction in two of the mutants. In the case of H3639P, our data support a model wherein the proline substitution compromises structural plasticity within an inter-helical loop in AAA5 that ultimately leads to a loss of activity in a large fraction of the motors, potentially as a consequence of protein misfolding. This conclusion is based on the reduced localization phenotype ([Figure 5B and C](#fig5){ref-type="fig"}) that is rescued by flanking glycines ([Figure 6F](#fig6){ref-type="fig"}) and proteasome inhibition ([Figure 6G](#fig6){ref-type="fig"}), and the large proportion of non-motile microtubule-bound motors we observed in the single molecule assay ([Figure 4D](#fig4){ref-type="fig"}). Since nearly all these motors exhibit persistent microtubule binding but no motility (96%; see kymograph in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), we propose that a structural defect within the AAA ring is compromising the ability of nucleotide binding or hydrolysis to communicate with the microtubule-binding domain. It is interesting to note that the small fraction of motors that do exhibit processive motility in vitro (4.5%) move at velocities that are roughly similar to wild-type motors (80 versus 58 nm/sec for wild-type and H3639P, respectively). We observed a similar phenomenon during dynein-mediated spindle translocation in vivo (42 versus 22 nm/sec). These findings are consistent with the notion that a small fraction of the motors are capable of overcoming folding defects to adopt a native, motility-competent conformation.

Subsequent to initiating this study, another group published findings describing the in vitro motility properties of a subset of the mutants analyzed here ([@bib25]). In this study, the authors utilized a recombinant human dynein in complex with dynactin and the adaptor BicD2 to assess single molecule motility parameters. With only two exceptions (E109I and N283R), the findings from this highly informative study largely corroborate our own data in that the dynein mutants assessed compromised the processivity of dynein-dynactin complexes (see [Figure 8A](#fig8){ref-type="fig"}, left, 'D'). For instance, the two mutants with the most severe phenotypic consequences were the same as those observed here (R1962C and H3822P). Although one of the exceptions -- E109I -- did not exhibit reduced processivity in our assays, the authors' observation that this mutation leads to a reduction in the number of processive motors ([@bib25]) is similar to our observation of reduced cellular dynein-dynactin activity for this mutant ([Figure 8A](#fig8){ref-type="fig"}, left, 'A'). Interestingly, this same study also noted a similar correlation between degree of dynein dysfunction and disease type (*i.e.*, the most severe phenotypes correlated with MCD, while the least severe phenotypes correlated with SMA-LED), providing further validation for budding yeast as a model system for dynein studies.

In summary, we have established yeast as a medium-throughput model system that can be used to assess the molecular basis for dysfunction of disease-correlated dynein mutants. Our rapid and economical toolbox can be easily applied to understand the underlying basis for dysfunction in newly identified dynein mutants found in patients suffering from neurological diseases. We have also demonstrated the feasibility of rapidly testing hypotheses generated from our battery of assays using the wealth of available structural information that is available for dynein and its regulators.

Materials and methods {#s4}
=====================

Media and strain construction {#s4-1}
-----------------------------

Strains are derived from either W303 or YEF473A ([@bib5]) and are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. We transformed yeast strains using the lithium acetate method ([@bib35]). Strains carrying mutations were constructed by PCR product-mediated transformation ([@bib48]) or by mating followed by tetrad dissection. Proper tagging and mutagenesis was confirmed by PCR, and in most cases sequencing (all point mutations were confirmed via sequencing). Fluorescent tubulin-expressing yeast strains were generated using plasmids and strategies described previously ([@bib53]; [@bib83]). Yeast synthetic defined (SD) media was obtained from Sunrise Science Products (San Diego, CA).

Plasmid generation {#s4-2}
------------------

For expression and purification of human dynein complex mutants (or wild-type), mutations were engineered into the human dynein heavy chain (DHC)-containing plasmid, pbiG1a:6His-ZZ-SNAPf-DHC1. We used Gibson assembly to engineer point mutations -- C1932S, R1962C, or both -- into this plasmid. The PmeI-digested gene expression cassette from this plasmid was co-assembled with the PmeI-digested poly-gene cassette from pbiG1b:IC2/LIC2/Tctex1/Robl1/LC8 (encoding all dynein accessory chains) into PmeI-digested pbiG2ab using biGBac cloning strategies as previously described ([@bib95]) (all wild-type plasmids were kind gifts from Andrew Carter). The final, sequence-verified plasmids (wild-type and mutant variants of pbiG2ab:6His-ZZ-SNAPf-DHC1/IC2/LIC2/Tctex1/Robl1/LC8) were used to generate recombinant baculoviral genomes by Tn7 transposition into DH10Bac cells (Life Technologies). White, PCR-confirmed colonies were inoculated into LB media supplemented with 7 µg/ml gentamycin, 10 µg/ml tetracycline and 50 µg/ml kanamycin and grown overnight at 37°C. Bacmid preparation was performed as described previously ([@bib102]), stored at 4°C, and used within 2 weeks for subsequent virus production (see below).

Protein purification {#s4-3}
--------------------

Purification of yeast dynein (ZZ-TEV-Dyn1-HALO, under the native *DYN1* promoter; or, ZZ-TEV-6His-GFP-3HA-GST-dynein~331~-HALO, under the control of the galactose-inducible promoter, *GAL1p*) was performed as previously described ([@bib14]; [@bib29]). Briefly, yeast cultures were grown in YPA supplemented with either 2% glucose (for full-length dynein) or 2% galactose (for GST-dynein~331~), harvested, washed with cold water, and then resuspended in a small volume of water. The resuspended cell pellet was drop frozen into liquid nitrogen and then lysed in a coffee grinder (Hamilton Beach). After lysis, 0.25 vol of 4X dynein lysis buffer (1X buffer: 30 mM HEPES, pH 7.2, 50 mM potassium acetate, 2 mM magnesium acetate, 0.2 mM EGTA) supplemented with 1 mM DTT, 0.1 mM Mg-ATP, 0.5 mM Pefabloc SC (concentrations for 1X buffer) was added, and the lysate was clarified at 22,000 x g for 20 min. The supernatant was then bound to IgG sepharose six fast flow resin (GE) for 1--1.5 hr at 4°C, which was subsequently washed three times in 5 ml lysis buffer, and twice in TEV buffer (50 mM Tris, pH 8.0, 150 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 0.005% Triton X-100, 10% glycerol, 1 mM DTT, 0.1 mM Mg-ATP, 0.5 mM Pefabloc SC). To fluorescently label the motors for single molecule analyses, the bead-bound protein was incubated with either 6.7 µM HaloTag-AlexaFluor660 (Promega) for 10 min at room temperature. The resin was then washed four more times in TEV digest buffer, then incubated in TEV buffer supplemented with TEV protease for 1--1.5 hr at 16°C. Following TEV digest, the beads were pelleted, and the resulting supernatant was aliquoted, flash frozen in liquid nitrogen, and stored at −80°C.

The human dynein complex was expressed and purified from insect cells (ExpiSf9 cells; Life Technologies) as previously described with minor modifications ([@bib102]; [@bib77]). Briefly, 4 ml of ExpiSf9 cells at 2.5 × 10^6^ cells/ml, which were maintained in ExpiSf CD Medium (Life Technologies), were transfected with 1 µg of bacmid DNA (see above) using ExpiFectamine (Life Technologies) according to the manufacturer's instructions. 5 days following transfection, the cells were pelleted, and 1 ml of the resulting supernatant (P1) was used to infect 300 ml of ExpiSf9 cells (5 × 10^6^ cells/ml). 72 hr later, the cells were harvested (2000 x g, 20 min), washed with phosphate buffered saline (pH 7.2), pelleted again (1810 x g, 20 min), and resuspended in an equal volume of human dynein lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 10% glycerol, 1 mM DTT, 0.1 mM Mg-ATP, 1 mM PMSF). The resulting cell suspension was drop frozen in liquid nitrogen and stored at −80°C. For protein purification, 30 ml of additional human dynein lysis buffer supplemented with cOmplete protease inhibitor cocktail (Roche) was added to the frozen cell pellet, which was then rapidly thawed in a 37°C water bath prior to incubation on ice. Cells were lysed in a dounce-type tissue grinder (Wheaton) using ≥ 150 strokes (lysis was monitored by microscopy). Subsequent to clarification at 40,000 x g, 45 min, the supernatant was applied to 2 ml of IgG sepharose fast flow resin (GE) pre-equilibrated in human dynein lysis buffer, and incubated at 4°C for 2--4 hr. Beads were then washed with 50 ml of human dynein lysis buffer, and 50 ml of human dynein TEV buffer (50 mM Tris pH 7.4, 150 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 10% glycerol, 1 mM DTT, 0.1 mM Mg-ATP). The bead-bound protein was incubated with 3 µM SNAP-Surface Alexa Fluor 647 (NEB) for 40--60 min at 4°C (to fluorescently label the protein), washed five times in human dynein TEV buffer, then incubated with TEV protease overnight at 4°C. The next morning, the recovered supernatant was applied to a Superose six gel filtration column (GE) equilibrated in GF150 buffer (25 mM HEPES pH 7.4, 150 mM KCl, 1 mM MgCl~2~, 5 mM DTT, 0.1 mM Mg-ATP) using an AKTA Pure. Peak fractions (determined by UV 260 nm absorbance and SDS-PAGE) were pooled, concentrated, aliquoted, flash frozen, then stored at −80°C.

Cell lysis and immunoblotting {#s4-4}
-----------------------------

Yeast cultures were grown to similar mid-log phase densities (OD600 \~ 2) in 4 ml SD media, and harvested. Cell pellets were resuspended in 0.2 ml of 0.1 M NaOH and incubated for 10 min at room temperature as described ([@bib36]). Following centrifugation, the resulting cell pellet was resuspended in sample buffer. Equal amounts of total cell lysate (as determined from cell density prior to lysis) were loaded into each lane, transferred to PVDF and probed with a monoclonal anti-GFP antibody (at 1:250; Abm) followed by an HRP-conjugated goat anti-mouse antibody (at 1:10,000; Jackson ImmunoResearch Laboratories). Electroblotting to PVDF was performed in 25 mM Tris, 192 mM glycine supplemented with 0.05% SDS and 20% methanol. Chemiluminescence signal was acquired with a Chemidoc MP (BioRad). Immunoblots were exposed (durations ranged from 2 to 5 min) without saturating the camera's pixels.

Single and ensemble molecule motility assays {#s4-5}
--------------------------------------------

The yeast dynein single-molecule motility assay was performed as previously described with minor modifications ([@bib14]). Briefly, flow chambers constructed using slides and plasma cleaned and silanized coverslips attached with double-sided adhesive tape were coated with anti-tubulin antibody (8 μg/ml, YL1/2; Accurate Chemical and Scientific Corporation) then blocked with 1% Pluronic F-127 (Fisher Scientific). Taxol-stabilized microtubules assembled from unlabeled and fluorescently-labeled porcine tubulin (10:1 ratio; Cytoskeleton) were introduced into the chamber. Following a 5--10 min incubation, the chamber was washed with dynein lysis buffer (see above) supplemented with 20 μM taxol, and then purified dynein motors were introduced in the chamber. After a 1 min incubation, motility buffer (30 mM HEPES pH 7.2, 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 1 mM Mg-ATP) supplemented with 0.05% Pluronic F-127, 20 µM taxol, and an oxygen-scavenging system (1.5% glucose, 1 U/ml glucose oxidase, 125 U/ml catalase) was added. TIRFM images were collected using a 1.49 NA 100X TIRF objective on a Nikon Ti-E inverted microscope equipped with a Ti-S-E motorized stage, piezo Z-control (Physik Instrumente), and an iXon X3 DU897 cooled EM-CCD camera (Andor). 488 nm, 561 nm, and 640 nm lasers (Coherent) were used along with a multi-pass quad filter cube set (C-TIRF for 405/488/561/638 nm; Chroma) and emission filters mounted in a filter wheel (525/50 nm, 600/50 nm and 700/75 nm; Chroma). We acquired images at 2 s intervals for 8 min. Velocity and run length values were determined from kymographs generated using the MultipleKymograph plugin for ImageJ (<http://www.embl.de/eamnet/html/body_kymograph.html>).

Human dynein-mediated microtubule gliding assays were performed as previously described ([@bib102]) with minor modifications. Briefly, flow chambers were prepared by affixing an ethanol-flamed coverslip to a glass slide using double-stick tape. The chamber was then incubated on an ice block, washed with 1% Pluronic F-127, following by addition of purified dynein (five chamber volumes of 60 nM dynein complex). Unbound motors were washed out with GF150 buffer. Subsequently, motility buffer (30 mM HEPES pH 7.0, 50 mM KCl, 5 mM MgSO4, 1 mM EGTA, 1 mM DTT, 2.5 mM Mg-ATP, 40 µM taxol) supplemented with 1.5% glucose, the oxygen scavenging system (see above), and 150 nM fluorescent microtubules was added to the chamber. Images were acquired every 1 s (for wild-type) or 5 s (for mutants), and velocity values were determined from kymographs generated as above.

Live cell imaging experiments {#s4-6}
-----------------------------

For the single time point spindle position assay, the percentage of cells with a misoriented anaphase spindle was determined after growth overnight (12--16 hr) at a low temperature (16°C), as previously described ([@bib45]; [@bib50]; [@bib82]). A single z-stack of wide-field fluorescence images was acquired for mRuby2-Tub1. For the spindle dynamics assay, cells were arrested with hydroxyurea (HU) for 2.5 hr, and then mounted on agarose pads containing HU for fluorescence microscopy. Full Z-stacks (23 planes at 0.2 µm spacing) of GFP-labeled microtubules (GFP-Tub1) were acquired every 10 s for 10 min on a stage pre-warmed to 30°C. To image dynein localization in live cells, cells were grown to mid-log phase in SD media supplemented with 2% glucose, and mounted on agarose pads. Images were collected on a Nikon Ti-E microscope equipped with a 1.49 NA 100X TIRF objective, a Ti-S-E motorized stage, piezo Z-control (Physik Instrumente), an iXon DU888 cooled EM-CCD camera (Andor), a stage-top incubation system (Okolab), and a spinning disc confocal scanner unit (CSUX1; Yokogawa) with an emission filter wheel (ET525/50M for GFP, and ET632/60M for mRuby2; Chroma). Lasers (488 nm and 561 nm) housed in a LU-NV laser unit equipped with AOTF control (Nikon) were used to excite GFP and mRuby2, respectively. The microscope was controlled with NIS Elements software (Nikon).

Statistical analyses {#s4-7}
--------------------

Statistical tests were performed as described in the figure legends. Unpaired Welch's t tests (for gaussian distributed velocity data) and Mann-Whitney test (for exponentially distributed dispalcement data) were performed using Graphpad Prism. Z scores, which are a quantitative measure of difference between two proportions, were calculated using the following formula:$$Z = \frac{({\hat{p}}_{1} - {\hat{p}}_{2})}{\hat{p}(1 - \hat{p})(\frac{1}{n_{1}} + \frac{1}{n_{2}})}$$where:$$\hat{p} = \frac{y_{1} + y_{2}}{n_{1} + n_{2}}$$

Z scores were converted to two-tailed P values using an online calculator.

Coefficient of dynein dysfunction (CDD) score calculation {#s4-8}
---------------------------------------------------------

To calculate the CDD scores, we used the following approach which permitted a quantitative measure of difference between mean values obtained for wild-type versus those obtained for each mutant. Graphpad Prism was used to calculate q values (*i.e.*, the difference between the two means divided by the standard error of that difference), whereas Z scores were calculated as described above (all values are shown in [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). We then converted the q values and Z scores for each mutant (for each assay) into a 'normalized relative variance' score (nrv), which reflects the relative difference between two mean values (*e.g.*, between wild-type and mutant 1; as reflected in the Z scores and q values, or 'v'), where nrv = \|v\|/v~max~ for each range of scores (for each column shown in [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). To convert the nrv values into a final CDD score for each mutant, we used the formula shown in [Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}. Briefly, the nrv values for each assay for a given mutant was added, with the spindle positioning nrv (nrv~SP~) weighed five times that of the others, as described within the Results. In the two cases where a value wasn't determined (due to insufficient observations, such as in the case for neck transit success for the H3639P mutant), the denominator was reduced from 6 to 5. In the two instances where the Z score for spindle positioning was negative (due to a lower number of mispositioned spindles being observed in K540C and D2439K cells than in wild-type cells; see [Figure 1B](#fig1){ref-type="fig"}), we adjusted the values to 0 so as to avoid them skewing the nrv~SP~ values.
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Thank you for submitting your article \"Molecular basis for dyneinopathies reveals insight into dynein regulation and dysfunction\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Anna Akhmanova as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Richard J McKenney (Reviewer \#2); Giampietro Schiavo (Reviewer \#3).

The reviewers have discussed the reviews with one another and I have drafted this decision to help you prepare a revised submission.

Summary:

Your manuscript represents a tour-de-force analysis of cytoplasmic dynein mutations that have been previously discovered in human patients. You use a budding yeast system to perform in vivo and in vitro analysis of a panel of dynein mutants that cause various human maladies. This study nicely builds on previous work from Bullock lab (Hoang et al.) by combining in vitro measurements, which largely agree with the previously published data, with a range of in vivo assays to assess particular cellular defects associated with each mutation. We felt think this paper will be broadly interesting to readers and will serve as a resource and example of how to approach the characterization of dynein mutations discovered in the future.

The reviewers were supportive of publishing the work in *eLife* after the following essential revisions have been addressed.

Essential revisions:

1\) Were the single molecule data in Figure 4 derived from one protein preparation per variant? If so, data needs to be provided that supports the reproducibility of results between different preparations. For example, the authors could present data comparing the consistency of values for three wild-type dynein preps, or for a subset of mutants. The authors should state how many preps were tried with each mutant and each assay.

2\) The authors need to compare the expression levels of the different mutations in yeast. Can they rule out that some of the mutations affect protein levels?

3\) The authors should verify the amount of yeast dynactin (NIP100) associated to the different mutants via direct immunoprecipitation. These results would greatly help them to reach firm conclusions regarding the points raised in the third paragraph of the Discussion.

Other points:

1\) In Figure 7G the degree of rescue for the double mutant is actually very low (note the split y-axis). The authors should make this clearer in the text and discuss the possible reasons.

2\) Poirier et al. (2013) described R3384Q. Is R3384N, which is modeled by Marzo et al. in the current study, also a human mutation?

3\) It would be helpful for the reader to see directly which mutations were tested in the 2017 study. This could, for example, be added in the graphic in Figure 8A.

4\) Including the amino acid positions for the human mutations in parentheses in Figure 1A would make it easier to cross reference studies.

5\) Figure 3B. The identity of each channel should be labeled in the figure for clarity.

6\) \'Stabilized\' is spelled incorrectly in Figure 4A.

7\) Figure 2 legend: state what i.o. means.

8\) \"Moreover, combining C1822S with R1852V led to no degree of rescue\". Do the authors mean compared to each of the single mutants? This could be clarified.

9\) \"Compensatory mutation rescues motility of human dynein mutant\". It would be more accurate to say that the mutation suppresses or partially suppresses the mutant phenotype.

10\) For the parameters in Figure 2 what are the typical values for the full dynein mutant? This information is not essential but if it is available it would help the reader judge the scale of the effects caused by the disease mutations.

11\) The authors should be careful with color usage in Figure 1A (and all figures). Some of the dynein domains are the same color as the annotated mutations.

12\) Is the neck-transit arrow pointing in the correct direction in Figure 2A, top panel? The movement in the images appears opposite to the arrow.

13\) The observation of potential co-translational dimerization is intriguing. The authors could cite and discuss the recent finding of DynAPs in the assembly of ciliary dyneins: <https://elifesciences.org/articles/38497>.

14\) The color-coding of mutations in the bar charts is helpful and should be displayed in all figures. For instance it is missing in Figures 3 and 4.

15\) The authors fail to discuss prior literature on the characterized dynein mutations that cause similar phenotypes in other organisms such as mice (i.e. LOA, CRA, SWA mutations).

16\) The increased run-length for K1475Q is intriguing. The authors should measure single molecule intensities and compare to WT motors to be sure this isn\'t due to aggregation.

17\) I don\'t understand the conclusion that the full-length R1852C mutant motors are aggregated/misfolded but the minimal motor construct is not. More explanation is needed here. Why would the mutation in the motor domain more strongly affect the full-length motor versus the truncated motor?

18\) Did the authors try adding in different concentrations or types of reducing agents to their in vitro assays to determine if an ectopic disulfide bond really is to blame for the phenotypes?

19\) It's hard to follow the logic of why the authors jumped to the conclusion that a protein degradation response was to blame for the defects in H3639P mutant cells?

20\) It would be more transparent to plot most of the data points either directly on to the bar charts or replace the bar charts with box and whisker plots.

21\) The Abstract states there is no correlation between mutations and disease state, but then the authors find one. Should the first statement be \"There is no known correlation \[\...\]\"?

22\) Figure 1: the authors should add the meaning of CC and DD in the legend of panel A and use the green color to indicate the bar for K1475Q (mutation in the linker domain) in panel B.

23\) The authors should try and remove some redundant wording (e.g. subsection "Single molecule motility assays reveal insight into dynein-intrinsic dysfunction ": the content of the parentheses in the first paragraph \"e.g. Pac.1\...\" is redundant in light of the following two paragraphs) and modify some sentences (e.g. the kymograph in Figure 4---figure supplement 1 readily displays an increase in speed of K1475Q motors; however, it is difficult, if not impossible, to evince from this figure an increase in run length or in the fraction of active motors).

24\) Likewise, the authors should consider being a little bit more cautious in some of their conclusions (e.g. it is almost impossible to rule out a contribution of adaptors and accessory factors to the phenotype observed in mammalian cells) or speculations (geometric constrains limiting the amount of motor complexes engaged in transport of a vesicle -- an organelle is almost never perfectly round, which the exception of synaptic vesicles which are assembled after transport at synapses).

25\) Would it be possible to remove the term i.o. (insufficient observations) from some of the Figures (e.g. Figure 5) by increasing the number of observations or at least state the number of observed events in the figure legend?

26\) The readability of panels B and F of Figure 7 should be improved.

27\) The CDD calculation method should be included in the Material and methods section of the main text.

28\) The authors should consider including in the reference section some early references demonstrating the key role of cytoplasmic dynein in the nervous system of Metazoa (e.g. Saxton\'s lab, Drosophila; Fisher\'s lab, mouse), and some key reviews discussing the links between deficits in axonal transport and nervous system disorders, and the complexity of the clinical phenotypes caused by mutations in the DYNC1H1 gene.

29\) Please justify the decision of using one-way ANOVA OR unpaired t-test OR Z-scores for panels of the same figure (e.g. Figure 2). To the readers, these panels are indistinguishable in nature (they are derived from the same experimental dataset). This comment applies to the majority of main and supplemental figures.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Molecular basis for dyneinopathies reveals insight into dynein regulation and dysfunction\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Anna Akhmanova as the Senior Editor, a Reviewing Editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) Address the following comments about toning down the claims of novelty.

Some of the claims about the novelty of the finding that there is a correlation between disease type and strength of the mutations\' effects on dynein activity are too strong, and need to be toned down.

For example, the authors write in the Abstract \"In addition to revealing molecular insight into dynein regulation, our data reveal an unexpected correlation between the degree of dynein dysfunction and disease type\".

The last part of the sentence is misleading as Hoang et al., 2017, reached a similar conclusion:

\"Interestingly, of the 16 human or mouse mutations that support production of the recombinant dynein complex, the 6 with the strongest effects on dynein motility are associated with MCD in humans (Figure 6). All three SMALED mutations that could be assayed in the context of the purified motor complex fell into the class with the weakest effects (Figure 6). These mutations are among the group that only compromised run lengths of processive dynein-dynactin-BICD2N complexes. These findings raise the possibility that MCD and SMALED are caused by different degrees of inhibition of dynein motility, rather than inactivation of distinct dynein-related processes\".

Whilst the confirmation and extension of this correlation by Marzo et al. valuable, it would seem uncharitable not to mention that it had been reported before (and is therefore not unexpected to find this in the current study).

The authors could, for example, write in the Abstract that \"our data strengthen the evidence that different disease types arise from different degrees of dynein function\", and must include an acknowledgement in the main text (e.g. in the Discussion) that Hoang et al. proposed this previously based on their observations.

There is a similar statement in the last paragraph of the Introduction that also needs toning down.

2\) It was not clear to us from the legends to the new Figure 5---figure supplement 2 what the two images for each blot represent. Are these different blots of the same extracts, or from two different extracts per experiment? This information should be included in the legend.

10.7554/eLife.47246.038

Author response

> Essential revisions:
>
> 1\) Were the single molecule data in Figure 4 derived from one protein preparation per variant? If so, data needs to be provided that supports the reproducibility of results between different preparations. For example, the authors could present data comparing the consistency of values for three wild-type dynein preps, or for a subset of mutants. The authors should state how many preps were tried with each mutant and each assay.

The single molecule data displayed in Figure 4 are derived from at least two independent protein preparations, that were each used to acquire replicate single molecule data. We apologize for not including this information in our previous draft, which has now been added to the Figure 4 legend. To address the reviewers' concern about reproducibility between replicate data sets, we have now added data points to the plots in Figure 4 that represent the mean values measured from each replicate (see diamonds in Figure 4B-D). In addition to adding these data points to Figure 4, we have also added them to plots in Figures 2 (depicting the spindle dynamics assay in haploid cells) and 3 (depicting the spindle dynamics assay in diploid cells). We thank the reviewer for the suggestion.

> 2\) The authors need to compare the expression levels of the different mutations in yeast. Can they rule out that some of the mutations affect protein levels?

We have spent a considerable amount of time and effort over the last 2 months trying to develop optimal immunoblotting conditions for consistent and reproducible data that we could use to quantitate relative expression levels of each dynein mutant. Likely as a consequence of dynein's large mass and low expression levels, this has proven somewhat difficult. In particular, we have encountered difficulties obtaining consistent electroblotting efficiency to PVDF membrane. That being said, we have now included results (see Figure 5---figure supplement 2) from three independent immunoblots. These data indicate that the steady-state cytoplasmic levels of each dynein mutant is roughly similar. As part of our troubleshooting, we performed Ponceau S staining of several of these membranes, which revealed differences in transfer efficiency across each membrane (and from membrane to membrane). Unfortunately, it was difficult to identify an emerging pattern, as sometimes the transfer worked best in the middle of the membrane, and at other times closer to the edges. Thus, we have not included a loading control (which would need to be run on a separate gel and transferred separately), since such a control (e.g., tubulin) would not reveal the extent of transfer inefficiencies across each membrane. We attempted to scan and quantitate the Ponceau S-stained membrane, but the low degree of staining (as a consequence of the low percent acrylamide gel -- 5% -- and the somewhat harsh transfer conditions required to electroblot dynein to the PVDF) made it difficult to sufficiently detect the protein bands.

We have updated the manuscript to include these findings. We thank the reviewers for the suggestion.

> 3\) The authors should verify the amount of yeast dynactin (NIP100) associated to the different mutants via direct immunoprecipitation. These results would greatly help them to reach firm conclusions regarding the points raised in the third paragraph of the Discussion.

As suggested by the reviewer, we sought to provide additional support for conclusions discussed in our manuscript. In particular: "Given the auto-inhibited Phi particle exhibits reduced affinity for dynactin, the altered localization pattern of the mutant may be due to disruption of a similar autoinhibitory conformation in yeast, consequent increased dynactin binding, and thus an increase in the frequency of cortical off-loading events."Thus, if the K1475Q mutant indeed perturbs an autoinhibited conformation of dynein, then we would expect this mutant to exhibit an enhanced interaction with dynactin.

To test this, we chose to use a fluorescence microscopy-based method. The reasons for this were two-fold: (1) obtaining purified dynactin has thus far proven elusive (we have spent more than two years trying to obtain pure dynactin following methods outlined in Kardon et al., 2009 PNAS, and we are unable to reproduce these results); and, (2) we have spent much time and effort trying to develop a coimmunoprecipitation protocol, and the IP has either failed, or the protein of interest (e.g., Nip100-HA) bound non-specifically to the beads.

Thus, to determine whether the K1475Q mutant binds more readily to dynactin, we sought to measure the relative degree of dynein-mediated recruitment of dynactin to microtubule plus ends. Previous studies have shown that dynactin is directly recruited to microtubule plus ends by dynein (Moore et al., 2008 Traffic) but dynein does not require dynactin to associate with plus ends. Moreover, our own quantitative fluorescence microscopy-based measurements revealed that dynactin is limiting at plus ends with respect to dynein (\~3 dyneins: 1 dynactin; Markus et al., 2011). Thus, if K1475Q disrupts an autoinhibited conformation of dynein, then we predict that this mutant would recruit more dynactin to plus ends than wild-type dynein. We performed ratiometric measurements of dynein (Dyn1-3GFP) and dynactin (using Jnm1-3mCherry) in cells deleted for Num1 in order to prevent the offloading mechanism from complicating interpretation of our measurements. These data, which are presented in Figure 5---figure supplement 1, indeed reveal an increased ratio of dynactin to dynein^K1475Q^ with respect to wild-type dynein (from 1.07 to 1.52; p \< 0.0001). We thank the reviewer for the suggestion.

> Other points:
>
> 1\) In Figure 7G the degree of rescue for the double mutant is actually very low (note the split y-axis). The authors should make this clearer in the text and discuss the possible reasons.
>
> We have added a note in the text clarifying the low degree of rescue, and also discussed a possible reason for the difference between human and yeast rescue. We thank the reviewer for the suggestion.
>
> 2\) Poirier et al. (2013) described R3384Q. Is R3384N, which is modeled by Marzo et al. in the current study, also a human mutation?

Thanks to the reviewer's comment, we now realize we mistakenly generated R3201N instead of R3201Q (R3384 equivalent). Given the amount of time and work it would take to generate the R3201Q yeast mutants (for single molecule motility assays, and live cell imaging), and the amount of work that would be required to acquire and analyze data with R3201Q (and respective wild-type replicates), we propose leaving the data in with the caveat explicitly stated that the mutation that we analyzed is very similar to, but not identical to the one identified in the Poirer study.

We think the data are still valuable for the following reasons: (1) glutamine and asparagine differ from each other by only one methyl group, and are similarly distinct in their biochemical properties from arginine (both result in the loss of a positive charge); (2) all three microtubule-binding domain (MTBD) mutants (R3152N, K3160Q and R3201N) lead to similar phenotypes in the in vitro and in vivo activity assessments (see Figure 8A), suggesting that any mutation that leads to altered charge density at the microtubule-MTBD interface leads to a similar phenotype; (3) although the mutation is not necessarily modeled after a mutation found in patients, we think it provides valuable information pertaining to the importance of the native residues at this surface, and the consequences associated with mutations in this region.

We have added comments addressing this mistake to the legends for Figures 1 and 8 (from Figure 1 legend: "Note that we mistakenly substituted an asparagine for residue R3201 instead of a glutamine, the latter of which was identified as correlating with MCD. R3201N was used throughout this study.") We thank the reviewer for pointing out this mistake.

> 3\) It would be helpful for the reader to see directly which mutations were tested in the 2017 study. This could, for example, be added in the graphic in Figure 8A.
>
> As suggested by the reviewer, we have added red asterisks to the table in Figure 8A denoting which mutants were tested in the 2017 Hoang et al. (PNAS 2017) study. We thank the reviewer for the suggestion.
>
> 4\) Including the amino acid positions for the human mutations in parentheses in Figure 1A would make it easier to cross reference studies.
>
> As suggested, we have noted the human amino acid residues corresponding to the equivalent yeast residues in Figure 1A. We thank the reviewer for the suggestion. Please note that we have also indicated in this figure the mistaken amino acid substitution discussed above in point 2 (denoted with a ‡).
>
> 5\) Figure 3B. The identity of each channel should be labeled in the figure for clarity.
>
> This has been corrected. We thank the reviewer for pointing out this missing label.
>
> 6\) \'Stabilized\' is spelled incorrectly in Figure 4A.
>
> This has now been corrected. We thank the reviewer for pointing out this mistake.
>
> 7\) Figure 2 legend: state what i.o. means.
>
> This has been added. We thank the reviewer for pointing out this oversight.
>
> 8\) \"Moreover, combining C1822S with R1852V led to no degree of rescue\". Do the authors mean compared to each of the single mutants? This could be clarified.
>
> We indeed meant with respect to the R1852V single mutant. This has been clarified in the text. We thank the reviewer for pointing out this point of confusion.
>
> 9\) \"Compensatory mutation rescues motility of human dynein mutant\". It would be more accurate to say that the mutation suppresses or partially suppresses the mutant phenotype.
>
> We agree with the reviewer's suggestion, and have changed the header accordingly.
>
> 10\) For the parameters in Figure 2 what are the typical values for the full dynein mutant? This information is not essential but if it is available it would help the reader judge the scale of the effects caused by the disease mutations.
>
> As mentioned above, we have now included data points on the plots in Figure 2 (as well as those in Figures 3 and 4) that represent the mean values measured for each independent replicate. Moreover, we have also included scatter plots for the velocity and displacement datasets to display the entirety of the data (see Figure 2---figure supplement 2B and C).
>
> 11\) The authors should be careful with color usage in Figure 1A (and all figures). Some of the dynein domains are the same color as the annotated mutations.
>
> We apologize for the confusing color usage in Figure 1A. We have changed the coloring in this figure to avoid overlap of mutations with domain labeling. With the exception of Figures 6 and 7 -- which focus on detailed characterizations of H3639P and R1852C, respectively -- we employed the tail (white), motor (blue), linker (magenta), and MTBD (yellow) standard defined in Figure 1A for the remaining figures. We hope the reviewer finds this to be sufficiently improved.
>
> 12\) Is the neck-transit arrow pointing in the correct direction in Figure 2A, top panel? The movement in the images appears opposite to the arrow.
>
> To clarify, the arrow was not meant to depict the direction of the neck transit, but the time frames over which the neck transit was occurring. We changed the arrows to lines, and clarified this point in the legend to Figure 2. We thank the reviewer for pointing out this confusing labeling.
>
> 13\) The observation of potential co-translational dimerization is intriguing. The authors could cite and discuss the recent finding of DynAPs in the assembly of ciliary dyneins: <https://elifesciences.org/articles/38497>.

It is indeed intriguing to speculate that assembly of cytoplasmic dynein complexes occurs in a manner analogous to that described in the Huizar et al., 2018 eLife paper. The authors of this study provide compelling evidence demonstrating that axonemal dynein complexes assemble in liquid-like organelles within the cytoplasm with the aid of axonemal dynein assembly factors. However, our findings only suggest that dimerization of the heavy chain occurs in a co-translational manner, and does not suggest anything with regard to dynein complex assembly occurring in a discrete organelle. In fact, the assembly of axonemal dynein complexes in the DynAPs was not observed to take place coincident with translation, or even in the presence of RNAs from which the complex components may be translating, which contrasts with what we observe in budding yeast.

> An example that is more analogous to what we have observed for DYN1 would be what was noted to occur with p53 (Nicholls et al., JBC 2002). In this study, the authors observed co-translational assembly of p53 dimers, but not higher-order (i.e., tetramers) oligomers. We have included this example in the latest iteration of our manuscript.
>
> 14\) The color-coding of mutations in the bar charts is helpful and should be displayed in all figures. For instance it is missing in Figures 3 and 4.
>
> We have now ensured that the color usage defined in Figure 1A (tail, white; motor, blue; linker, magenta; MTBD, yellow) is used throughout all figures, with the exception of Figures 6 and 7, which focus on detailed characterizations of H3639P and R1852C, respectively. We thank the reviewer for suggesting as much.
>
> 15\) The authors fail to discuss prior literature on the characterized dynein mutations that cause similar phenotypes in other organisms such as mice (i.e. LOA, CRA, SWA mutations).
>
> We have now included a brief discussion on the findings describing neuronal deficits in mouse models of dynein dysfunction (in the Introduction). We thank the reviewer for the suggestion.
>
> 16\) The increased run-length for K1475Q is intriguing. The authors should measure single molecule intensities and compare to WT motors to be sure this isn\'t due to aggregation.
>
> As suggested by the reviewer, we have now measured the fluorescence intensity values for single molecules of motile wild-type and K1475Q dynein. As shown in the new Figure 4---figure supplement 2, we did not observe any indication of motor aggregates in the single molecule assay. We thank the reviewer for the good suggestion.
>
> 17\) I don\'t understand the conclusion that the full-length R1852C mutant motors are aggregated/misfolded but the minimal motor construct is not. More explanation is needed here. Why would the mutation in the motor domain more strongly affect the full-length motor versus the truncated motor?
>
> This is an excellent question. We speculated that the truncated motor domain would be less susceptible to defects arising from the R1852C mutation (which, our data indicate are structural in nature) due the compact and simple nature of this fragment (i.e., does not associate with, or rely on accessory chains). That being said, the fact that the truncated R1852C mutant motor is more active than the full-length molecule is still a bit surprising to us. Without additional information, it is difficult to speculate further. However, we added a statement saying our data suggest "that the holoenzyme complex is more susceptible to defects arising from this mutation than is the truncated motor domain." We are still actively exploring this question, although it is unclear we will ever know the precise reason the truncation rescues activity of the R1852C mutant.
>
> 18\) Did the authors try adding in different concentrations or types of reducing agents to their in vitro assays to determine if an ectopic disulfide bond really is to blame for the phenotypes?

In an attempt to reverse the disulfide bond within the R1852C mutant, we have indeed tested varying concentrations of DTT and N-acetyl cysteine in our in vivo and in vitro assays. Specifically, we tried adding 5-10 mM DTT (for the duration of the hydroxyurea arrest: 2.5 hours) to R1852C mutant cells prior to imaging for the spindle dynamics assay, but observed no effect. We also tried adding 1-10 mM DTT, and 1-10 mM N-acetyl cysteine (in separate experiments) for as long as two hours prior to imaging R1852C mutant cells to try to rescue defects in the localization assay, but observed no effect. Finally, we tested up to an additional 5 mM DTT to the single molecule assay with R1852C to try to restore motility, but observed no effect.

> One simple explanation to account for the inability of the reducing agents to rescue the defects associated with R1852C is that the region of interest is not solvent accessible. Analysis of high resolution structures of the yeast dynein motor domain (pdb 4AKG) and human dynein-2 motor domain (pdb 4RH7) reveals this may be the case, as C1822S (or its human equivalent) is not apparent in either surface-rendered structure.
>
> 19\) It's hard to follow the logic of why the authors jumped to the conclusion that a protein degradation response was to blame for the defects in H3639P mutant cells?
>
> We apologize for the lack of clarity in this section. We originally came to this conclusion based on the following pieces of evidence: (1) the frequency of cells exhibiting Dyn1^H3639P^ foci is low with respect to wild-type cells (suggesting lower amounts of protein); (2) this frequency can be increased by flanking Pro3639 with glycines (suggesting increased levels with respect to H3639P); (3) this triple mutant rescues only one aspect of dynein function: the relative number of dynein-mediated spindle movement events (not the quality of the events; note it also didn't rescue any in vitro parameters). However, in light of our new immunoblot data, which does not show any significant differences in protein expression among the dynein mutants, we have changed our thinking. We now believe that the H3639P mutation simply compromises dynein folding, and this is the underlying reason for mistargeting and poor activity metrics. We have changed the language within the manuscript to reflect these new data and modified our conclusions accordingly.
>
> 20\) It would be more transparent to plot most of the data points either directly on to the bar charts or replace the bar charts with box and whisker plots.
>
> To improve transparency, we have added two new things to the figures: (1) as mentioned above, we have overlaid data points on plots in Figure 2, 3 and 4 that represent the mean values of each independent replicate; and, (2) we have included as supplementary material scatter plots displaying all data. Specifically, we added scatter plots for the following datasets:a) Velocity and displacement for spindle dynamics assay for haploid cells (new Figure 2---figure supplement 2A and B)b) Velocity and displacement for spindle dynamics assay for diploid cells (new Figure 3---figure supplement 1)c) Velocity and displacement for single molecule assays (new Figure 4---figure supplement 1A and B)d) Velocity and displacement for spindle dynamics assay for H3639P and related mutants (new Figure 6---figure supplement 1C and D)e) Velocity and displacement for single molecule assays for H3639P and related mutants (Figure 6---figure supplement 1H and I)f) Velocity and displacement for spindle dynamics assay for R1852C and related mutants (new Figure 7---figure supplement 2A and B)g) Velocity and displacement for single molecule assays for yeast (and human equivalent of) R1852C (R1962C) and related mutants (Figure 7---figure supplement 2C - E)
>
> 21\) The Abstract states there is no correlation between mutations and disease state, but then the authors find one. Should the first statement be \"There is no known correlation \[\...\]\"?

Indeed. Per the reviewer's suggestion, we changed the Abstract accordingly.

> 22\) Figure 1: the authors should add the meaning of CC and DD in the legend of panel A and use the green color to indicate the bar for K1475Q (mutation in the linker domain) in panel B.
>
> Per the reviewer's suggestion, we defined "CC", "DD" (and even "MTBD" which we noted was lacking) in the Figure 1 legend. We thank the reviewer for catching this oversight on our part. We also added a distinct color to clearly differentiate the linker domain mutation (K1475Q) throughout all relevant figures. We thank the reviewer for the suggestion.
>
> 23\) The authors should try and remove some redundant wording (e.g. subsection "Single molecule motility assays reveal insight into dynein-intrinsic dysfunction ": the content of the parentheses in the first paragraph \"e.g. Pac.1\...\" is redundant in light of the following two paragraphs) and modify some sentences (e.g. the kymograph in Figure 4---figure supplement 1 readily displays an increase in speed of K1475Q motors; however, it is difficult, if not impossible, to evince from this figure an increase in run length or in the fraction of active motors).

We would prefer to leave the parenthetical note in question as is. Although we discuss two of the molecules in that paragraph in more detail, the others are not mentioned. We think it best to use the short parenthetical note to allude to the complexities underlying dynein regulation in cells (and to include important citations).

> We would also prefer to leave the note in the manuscript referring the reader to the example kymograph for K1475Q (in Figure 4---figure supplement 1C). Although we don't expect the reader to evince fraction of active motors from this kymograph, we believe it nicely shows the increased run lengths and velocity parameters for this motor (note the large absence of shorter runs in this example with respect to wild-type).
>
> 24\) Likewise, the authors should consider being a little bit more cautious in some of their conclusions (e.g. it is almost impossible to rule out a contribution of adaptors and accessory factors to the phenotype observed in mammalian cells) or speculations (geometric constrains limiting the amount of motor complexes engaged in transport of a vesicle -- an organelle is almost never perfectly round, which the exception of synaptic vesicles which are assembled after transport at synapses).
>
> We have softened the language in question concluding that altered in vitro dynein motility parameters are necessarily indicative of dynein-intrinsic defects. We have also softened our speculation that geometric constrains of a vesicle limit the number of motors that can engage with a microtubule. We thank the reviewer for the suggestions.
>
> 25\) Would it be possible to remove the term i.o. (insufficient observations) from some of the Figures (e.g. Figure 5) by increasing the number of observations or at least state the number of observed events in the figure legend?
>
> With regard to increasing the number of observations for those mutants that exhibit fewer events (i.e., neck transit events in Figure 2) or foci (Figure 5), we think it would be unfair to sample a greater number of cells for some mutants than we did for others. We did our best to keep all sample sizes roughly equal. Of course, this means that some data sets will be smaller than others, such as in the case of dynein foci observations (since some mutant foci are present at lower frequencies) or in the case of neck transit events (since H3639P has such a low degree of dynein activity). However, as suggested by the reviewer, we have now included information in the figure legend describing the number of observed events for these two examples.
>
> 26\) The readability of panels B and F of Figure 7 should be improved.
>
> We have increased font sizes in the panels in question to improve the readability of this figure. We thank the reviewer for the suggestion.
>
> 27\) The CDD calculation method should be included in the Material and methods section of the main text.
>
> We have now included our method of CDD calculation in the Materials and methods section. We thank the reviewer for the suggestion.
>
> 28\) The authors should consider including in the reference section some early references demonstrating the key role of cytoplasmic dynein in the nervous system of Metazoa (e.g. Saxton\'s lab, Drosophila; Fisher\'s lab, mouse), and some key reviews discussing the links between deficits in axonal transport and nervous system disorders, and the complexity of the clinical phenotypes caused by mutations in the DYNC1H1 gene.
>
> Per the reviewer's suggestion, we have added references to important papers describing the role of dynein in neuronal transport, in its role in supporting neuronal health, and its implication in nervous system disorders. We apologize for this oversight, as the work in question laid the foundation for our understanding of dynein's role in neuronal health and neurodegenerative diseases. We thank the reviewer for the suggestion.
>
> 29\) Please justify the decision of using one-way ANOVA OR unpaired t-test OR Z-scores for panels of the same figure (e.g. Figure 2). To the readers, these panels are indistinguishable in nature (they are derived from the same experimental dataset). This comment applies to the majority of main and supplemental figures.

Thanks to the reviewer's question, we learned that we were using ANOVA incorrectly. This test assumes equal variances, which is inappropriate for the data on which we were applying this test. We have corrected this mistake, and applied the following three tests:

1\) Unpaired t test with Welch's correction (a.k.a., Welch's t test). We used this to determine significance between normally distributed datasets (i.e., velocity).

2\) Mann-Whitney test. We used this to determine significance between non-normally distributed datasets (i.e., displacement per event). Consistent with others, we find these datasets are exponentially distributed.

3\) Z score calculation. We used Z scores to determine significance between proportions, as is accepted practice (e.g., number of dynein events per minute per cell, fraction of neck transits that were successful, etc).

We have added a brief explanation for these tests in the Materials and methods section (under the "Statistical analyses" header). We thank the reviewer for asking this question, which prompted us to discover and correct our mistake.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Thank you for resubmitting your work entitled \"Molecular basis for dyneinopathies reveals insight into dynein regulation and dysfunction\" for further consideration at eLife. Your revised article has been favorably evaluated by Anna Akhmanova as the Senior Editor, a Reviewing Editor, and two reviewers.
>
> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) Address the following comments about toning down the claims of novelty.
>
> Some of the claims about the novelty of the finding that there is a correlation between disease type and strength of the mutations\' effects on dynein activity are too strong, and need to be toned down.
>
> For example, the authors write in the Abstract \"In addition to revealing molecular insight into dynein regulation, our data reveal an unexpected correlation between the degree of dynein dysfunction and disease type\".
>
> The last part of the sentence is misleading as Hoang et al., 2017, reached a similar conclusion:
>
> \"Interestingly, of the 16 human or mouse mutations that support production of the recombinant dynein complex, the 6 with the strongest effects on dynein motility are associated with MCD in humans (Figure 6). \[...\] These findings raise the possibility that MCD and SMALED are caused by different degrees of inhibition of dynein motility, rather than inactivation of distinct dynein-related processes\".
>
> Whilst the confirmation and extension of this correlation by Marzo et al. valuable, it would seem uncharitable not to mention that it had been reported before (and is therefore not unexpected to find this in the current study).
>
> The authors could, for example, write in the Abstract that \"our data strengthen the evidence that different disease types arise from different degrees of dynein function\", and must include an acknowledgement in the main text (e.g. in the Discussion) that Hoang et al. proposed this previously based on their observations.
>
> There is a similar statement in the last paragraph of the Introduction that also needs toning down.

We completely agree with this assessment, and apologize for this oversight on our part. We have made changes throughout our manuscript to include discussion describing these prior observations by Hoang et al. In particular, we have: (1) made the recommended change to language in the Abstract; (2) added language to the final paragraph of the Introduction alluding to these findings; and (3) added a sentence in the Discussion noting these prior observations by Hoang et al. We thank the reviewers for pointing out this oversight on our part.

> 2\) It was not clear to us from the legends to the new Figure 5---figure supplement 2 what the two images for each blot represent. Are these different blots of the same extracts, or from two different extracts per experiment? This information should be included in the legend.

To clarify, in the prior iteration of Figure 5---figure supplement 2, each independent immunoblot was arranged into two rows of 9 bands, each representing one of the 17 mutants plus wild-type (i.e., the top row included lysates from wild-type and 7 mutants up to W612C, and the bottom row included mutants from K1475Q to H3639P). We have rearranged the blots to avoid this confusion such that each independent blot is in a single row. We apologize for the confusing layout of the blots, and hope the revised version of this figure is more clear.
